

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted articles (R), abstracts (A), book reviews (B), and Workshop on Experimental Chemotherapy of Leprosy supplement (S).

Acid-fast,	
A cold staining method for acid-fast bacilli. Vasanthakumari, R., <i>et al.</i> (A)	389
Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. (A)	786
[Acid-fast bacilli in <i>Culex fatigans</i> .] Bona, S. H., <i>et al.</i> (A)	605
Influence of prior periodic acid oxidation on the acid-fastness of <i>M. leprae</i> . Dhople, A. M. (A)	179
[Modified method of counting acid-fast bacilli with agarose gel.] Li, F. (A)	388
The identification and characterization of acid-fast bacilli cultured on hyaluronic acid media and an evaluation of their etiologic role in leprosy. Ohashi, D. K. (A)	404
Acupuncture,	
The usefulness of acupuncture in leprosy. Jagirdar, P. C. (A)	185, 590
Adenosine triphosphate (ATP),	
An <i>in vitro</i> system using adenosine triphosphate and ³ H-thymidine to determine drug sensitivity of <i>M. leprae</i> . Dhople, A. M. and Green, K. J. (A)	172
Africa,	
[Differential diagnosis of leprous lesions in Africans.] Akimov, V. G. (A)	375
[Epidemiological profile of leprosy in Algeria.] Oughanem, M., <i>et al.</i> (A)	393
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. (A)	578
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., <i>et al.</i> (A)	576
[Studies on the tuberculosis infection in a cattle breeding area in sahelian Africa.] Rey, J. L., <i>et al.</i> (A)	396
<i>Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT)</i> . Harboe, M., ed. (B)	574
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. (A)	182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. (A)	183
Allergy,	
The relation between allergy and immunity in leprosy. Maier, M. E	116
Amyloid,	
Amyloid goiter—a case report. Dhopavkar, P. V., <i>et al.</i> (A)	173
Ansamycin,	
Effect of combined clofazamine and ansamycin therapy on <i>M. avium-M. intracellulare</i> bacteremia in patients with AIDS. Masur, H., <i>et al.</i> (A)	396
Antibody(ies),	
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., <i>et al.</i> (A)	178
Analysis of a leprosy-specific antibody epitope. Brown, W. B., <i>et al.</i> (A)	744
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. (A)	747
Analysis of monoclonal antibodies to <i>M. leprae</i> by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. (A)	594
Anti-mycobacterial antibodies in saliva. Abe, M., <i>et al.</i> (A)	742
Antibodies to a synthetic analog of phenolic glycolipid-I of <i>M. leprae</i> in healthy household contacts of patients with leprosy. Menzel, S., <i>et al.</i> (O)	617

Antibodies to phenolic glycolipid-I during long-term therapy; serial measurements in individual patients. Miller, R. A., <i>et al.</i> (O)	633
Antibodies to tubulin in patients with parasitic infections. Howard, M. K., <i>et al.</i> (A)	595
Antimycobacterial antibodies in <i>Dasypus novemcinctus</i> infected with <i>M. leprae</i> and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., <i>et al.</i> (A)	391
Antispermatozoal antibodies in leprosy with special reference to their morphological patterns. Gupta, S. C., <i>et al.</i> (A)	174
Attempts to produce erythema nodosum leprosum in <i>M. leprae</i> -infected nude nu/nu mice with monoclonal antibodies. Chehl, S., <i>et al.</i> (A)	410
Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with <i>M. lepraemurium</i> . Hoffenbach, A. and Bach, M.-A. (A)	390
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	745
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., <i>et al.</i> (O)	273
Dominant cell wall proteins of <i>M. leprae</i> recognized by monoclonal antibodies. Britton, W. J., <i>et al.</i> (A)	379
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A)	764
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., <i>et al.</i> (A)	598
Influence of route of inoculation on anti- <i>M. lepraemurium</i> antibody isotopes in murine leprosy. Hoffenbach, A., <i>et al.</i> (O)	305
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., <i>et al.</i> (A)	408
Monitoring of leprosy patients with antibodies to <i>M. leprae</i> phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., <i>et al.</i> (A)	409
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., <i>et al.</i> (A)	176
Serodiagnosis of leprosy; relationships between antibodies to <i>M. leprae</i> phenolic glycolipid-I and protein antigens. Levis, W. R., <i>et al.</i> (A)	381
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	743
Specific antigen and antibody to <i>M. leprae</i> in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., <i>et al.</i> (A)	594
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	406
The allyl group for protection in carbohydrate chemistry. Part 19. The coupling of allyl 2, 3-di- <i>O</i> -methyl-4- <i>O</i> -(3, 6-di- <i>O</i> -methyl- β -D-glucopyranosyl)- α -L-rhamnopyranoside to bovine serum albumin. Preparation of a diagnostic reagent for antibodies to the major glycolipid of <i>M. leprae</i> (the leprosy bacillus) in human sera. Gigg, J., <i>et al.</i> (A)	745
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with <i>M. leprae</i> . Vadiee, R., <i>et al.</i> , (A)	419
The limited spectrum of antinuclear antibodies in leprosy. Miller, R. A., <i>et al.</i> (A)	590
Thyroglobulin autoantibodies in leprosy. George, J., <i>et al.</i> (A)	174
Antigen(s),	
A recombinant 64 kilodalton protein of <i>M. bovis</i> bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., <i>et al.</i> (A)	594
Ability of the phenolic glycolipid-I antigen of <i>M. leprae</i> to elicit a positive Mitsuda response in the armadillo (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	299
Antigens of <i>M. leprae</i> in urine during treatment of patients with lepromatous leprosy. Olcén, P., <i>et al.</i> (A)	384

Cellular and humoral immune response to a phenolic glycolipid antigen (PGL-I) in patients with leprosy. Koster, F. T., <i>et al.</i> (A)	597
Characterization of the 36 K antigen of <i>M. leprae</i> . Klatser, P. R., <i>et al.</i> (A)	749
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of <i>M. leprae</i> , <i>M. tuberculosis</i> , <i>M. vaccae</i> , and <i>M. bovis</i> (BCG). Sinha, S., <i>et al.</i> (O)	42
Detection and characterization of antigens of <i>M. leprae</i> reacting with sera from leprosy patients. Sathish, M., <i>et al.</i> (A)	789
Development of a dot-ELISA for detection of leprosy antigenuria under field conditions. Kaldany, R.-R. J. and Nurlign, A. (A)	747
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., <i>et al.</i> (A)	188
Efficient mapping of protein antigenic determinants. Mehra, V., <i>et al.</i> (A)	382
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with <i>M. leprae</i> . Samuel, N. M., <i>et al.</i> (A)	753
Genes for the major protein antigens of <i>M. tuberculosis</i> : the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. (A)	595
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A)	764
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., <i>et al.</i> (O)	261
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. (A)	746
Interferon-gamma induces the expression of major histocompatibility complex antigens by <i>in vitro</i> cultured murine Schwann cells. Mshana, R. N., <i>et al.</i> (A)	781
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. (A)	407
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., <i>et al.</i> (A)	743
<i>M. leprae</i> antigen-induced suppression of T cell proliferation <i>in vitro</i> . Kaplan, G., <i>et al.</i> (A)	596
Macrophages infected <i>in vitro</i> with live mycobacteria fail to express Ia antigen after stimulation with lymphokine. Mshana, R. N., <i>et al.</i> (A)	407
[Method of immunization with BCG-M vaccine with reduced antigenic content.] Yablokova, T. B., <i>et al.</i> (A)	765
Methods for the detection of a specific <i>M. leprae</i> antigen in the urine of leprosy patients. Kaldany, R.-R., <i>et al.</i> (A)	596
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., <i>et al.</i> (A)	408
MPB59, a widely crossreacting protein of <i>M. bovis</i> BCG. Wiker, H. G., <i>et al.</i> (A)	610
Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., <i>et al.</i> (A)	775
Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., <i>et al.</i> (O)	651
Resistance to <i>M. lepraemurium</i> is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens <i>in vitro</i> . Brett, S. J. and Butler, R. (A)	389
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., <i>et al.</i> (A)	176
Serodiagnosis of leprosy: relationships between antibodies to <i>M. leprae</i> phenolic glycolipid-I and protein antigens. Levis, W. R., <i>et al.</i> (A)	381
Seroepidemiological study on 724 household contacts of leprosy patients in French Polynesia using disaccharide-octyl-BSA as antigen. Chanteau, S., <i>et al.</i> (O)	626
Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., <i>et al.</i> (A)	743
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	743
Specific antigen and antibody to <i>M. leprae</i> in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., <i>et al.</i> (A)	594

Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. Hunter, S. W., <i>et al.</i> (A)	179
Suppression of delayed hypersensitivity skin reactions to tuberculin by <i>M. leprae</i> antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., <i>et al.</i> (A)	600
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. (A)	189
The carbohydrate-containing antigens of <i>M. leprae</i> . Brennan, P. J. (A)	755
The HLA antigens and leprosy in Korea. Kim, S. J., <i>et al.</i> (A)	183
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., <i>et al.</i> (A)	779
Argentina,	
80th anniversary of Asociación Argentina de Dermatología. (N)	363
Armadillo(s),	
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with <i>M. leprae</i> . Portaels, F., <i>et al.</i> (A)	180
A Mexican armadillo (<i>Dasypus novemcinctus</i>) colony for leprosy research. Quesada-Pascual, F., <i>et al.</i> (C)	716
Ability of the phenolic glycolipid-I antigen of <i>M. leprae</i> to elicit a positive Mitsuda response in the armadillo (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	299
Antimycobacterial antibodies in <i>Dasypus novemcinctus</i> infected with <i>M. leprae</i> and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., <i>et al.</i> (A)	391
Congenital transmission of leprosy in armadillos. Hastings, R. C., <i>et al.</i> (A)	420
Cultivable mycobacteria isolated from 32 newly captured armadillos (<i>Dasypus novemcinctus</i>) from Louisiana. (U.S.A.) Portaels, F., <i>et al.</i> (A)	788
Detection of trehalose monomycolate in <i>M. leprae</i> grown in armadillo tissues. Dhariwal, K. R., <i>et al.</i> (A)	387, 755
[Histochemical study of reverse reactions in <i>M. leprae</i> -infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. (A)	757
Lepromatous placentitis and intrauterine fetal infection in lepromatous nine-banded armadillos (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (A)	391
Naturally acquired leprosy in the nine-banded armadillo; a decade of experience 1975–1985. Walsh, G. P., <i>et al.</i> (A)	181
Prevalence and significance of positive Mitsuda reaction in the nine-banded armadillo (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	685
Seroepidemiology of leprosy in wild armadillos (<i>Dasypus novemcinctus</i>). Truman, R. W., <i>et al.</i> (A)	419
Surveillance for <i>M. leprae</i> infections in a community of nine-banded armadillos. Stallknecht, D. E., <i>et al.</i> (A)	420
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with <i>M. leprae</i> . Vadiee, R., <i>et al.</i> (A)	419
Thorns in armadillo ears and noses and their role in the transmission of leprosy. Job, C. K., <i>et al.</i> (A)	182
Arthritis,	
Arthritis induced by a T-lymphocyte clone that responds to <i>M. tuberculosis</i> and to cartilage proteoglycans. van Eden, W., <i>et al.</i> (A)	188
Assay(s), (see also ELISA),	
A single cell assay for the study of γ -interferon formation in leprosy patients. Lindh, J., <i>et al.</i> (A)	382
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of <i>M. leprae</i> viability. Harshan, K. V., <i>et al.</i> (O)	316
Australia,	
Australia's last leprosarium closed and Hansen's disease symposium at Perth. Cassidy, J. J. (N)	165

B663 (see Clofazimine)**Bacilli,**

- A cold staining method for acid-fast bacilli. Vasanthakumari, R., *et al.* (A) 389
- Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. (A) 786
- [Acid-fast bacilli in *Culex fatigans*.] Bona, S. H., *et al.* (A) 605
- An unusual case of untreated lepromatous leprosy with rare bacilli; an immunologic follow-up. Gelber, R. H. and Mohaghehpour, N. (C) 353
- Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium*. Hoffenbach, A. and Bach, M.-A. (A) 390
- Exochelin-mediated iron acquisition by the leprosy bacillus *M. leprae*. Hall, R. M. and Ratledge, C. (A) 387
- [Lysosomes and leprosy bacilli.] Fukunishi, Y. (A) 181
- [Modified method of counting acid-fast bacilli with agarose gel.] Li, F. (A) 388
- Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercule bacilli. Hunter, S. W., *et al.* (A) 179
- The identification and characterization of acid-fast bacilli cultured on hyaluronic acid media and an evaluation of their etiologic role in leprosy. Ohashi, D. K. (A) 404

Bacteremia,

- Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* (A) 396
- [Incidence of bacteremia in leprosy and a comparison of various detecting methods.] Ye, S.-H., *et al.* (A) 378

Bacterial index (BI),

- [Staining of *M. leprae*: comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., *et al.* (A) 387

Bacteriology,

- [Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* (A) 739

BCG (bacille Calmette-Guérin),

- A recombinant 64 kilodalton protein of *M. bovis* bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., *et al.* (A) 594
- BCG-induced suppressor T cells optimal conditions for *in vitro* induction and mode of action. Mustafa, A. S. and Godal, T. (A) 187
- Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* (A) 750
- Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae*, *M. tuberculosis*, *M. vaccae*, and *M. bovis* (BCG). Sinha, S., *et al.* (O) 42
- Effect of oral exposure of *M. avium intracellulare* on the protective immunity induced by BCG. Narayanan, S., *et al.* (A) 608
- Immunization of mice with *M. leprae/M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. (O) 293
- Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M., *et al.* (O) 646
- Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.* (A) 743
- [Method of immunization with BCG-M vaccine with reduced antigenic content.] Yablokova, T. B., *et al.* (A) 765
- MPB59, a widely cross-reacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* (A) 610
- Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* (A) 595
- The characterization and immunoreactivity of a 70 kD protein common to *M. leprae* and *M. bovis* (BCG). Britton, W. J., *et al.* (A) 744

Biochemistry,

- Biochemical studies on *M. leprae*. Prabhakaran, K., *et al.* (A) 389
- Enzymes and other biochemically active components of mycobacteria. Draper, P. (A) 755

- Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. (A) 746
- [Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* (A) 763
- Biopsy,**
- Hansen's disease: a new endemic focus in the Piacenza Province (Italy)? A description of four diagnosed cases by cutaneous biopsy. Paties, C., *et al.* (A) 393
- Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* (O) 88
- Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., *et al.* (O) 333
- Blood,**
- Blood dapsone levels in leprosy patients treated with acedapsone. George, J. and Balakrishnan, S. (A) 371
- The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., *et al.* (A) 779
- Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* (A) 416
- Book reviews,**
- A Spot Test for Dapsone in Urine* by Huikeshoven, Han. Hastings, R. C. (B) 574
- Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China.* (B) 574
- Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy.* (B) 737
- Research Activities of the National Institute for Leprosy Research.* Abe, M., ed. . . . (B) 170
- Studies on Leprosy in Bombay.* Hastings, R. C. (B) 170
- Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT).* Harboe, M., ed. (B) 574
- The Mycobacteria: A Sourcebook (in two parts).* Kubica, G. P. and Wayne, L. G., eds. Franzblau, S. G. (B) 369
- Tropical Disease Research: A Global Partnership.* (B) 737
- World Health Statistics Quarterly, Vol. 39, No. 2, 1986.* Maxwell, B. A. (B) 170
- Borderline leprosy,**
- An unusual bullous reaction in borderline leprosy. Singh, K. (A) 592
- HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* (O) 261
- Multiple relapses in borderline leprosy—a case report. Ramachandran, A. and Seshadri, P. S. (A) 591
- [Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu, J., *et al.* (A) 382
- Brazil,**
- Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., *et al.* (O) 435
- Catalase,**
- Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* (A) 388
- Cell(s), (see also specific cells),**
- Accessory function of cells isolated from *M. leprae*-induced granulomas. Montreewasawat, N., *et al.* (A) 383
- Dominant cell wall of *M. leprae* recognized by monoclonal antibodies. Britton, W. J., *et al.* (A) 379
- [*In situ* characterization of immune cells in the annular lesions of leprosy.] Lee, C. W., *et al.* (A) 597

Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. (A)	407
[II. <i>M. lepraemurium</i> in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., <i>et al.</i> (A)	742
Single bacterial cell mass analysis: a rapid test method in leprosy therapy control. Seydel, U. and Lindner, B. (A)	603
Suppressor response in lepromatous leprosy patients; role of Leu2a cells. Sasiain, M. del C., <i>et al.</i> (A)	385
The cell wall of <i>M. leprae</i> ; isolation, composition, and immunogenicity. Brennan, P. J., <i>et al.</i> (A)	782
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., <i>et al.</i> (A)	754
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy patient contacts. Converse, P. J., <i>et al.</i> (A)	779
Thymidine uptake as an indicator of cell ability and <i>in vitro</i> growth of <i>M. leprae</i> . Dhople, A. M. (A)	402
Cells, B,	
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., <i>et al.</i> (A)	598
Cells, Langerhans',	
Distribution and turnover of Langerhans' cells during delayed immune responses in human skin. Kaplan, G., <i>et al.</i> (A)	748
[Ultrastructure of Langerhans' cells in the skin of borderline leprosy patients.] Liu, J., <i>et al.</i> (A)	382
Cells, natural killer (NK),	
The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorobenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., <i>et al.</i> (A)	610
Cells, Schwann,	
Adherence of <i>M. leprae</i> to Schwann cells <i>in vitro</i> . Itty, B. M., <i>et al.</i> (A)	381
Drs. Band and Talwar reply. Band, H. and Talwar, G. P. (C)	563
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with <i>M. leprae</i> . Samuel, N. M., <i>et al.</i> (A)	753
Interferon-gamma induces the expression of major histocompatibility complex antigens by <i>in vitro</i> cultured murine Schwann cells. Mshana, R. N., <i>et al.</i> (A)	781
Schwann cells and <i>M. leprae</i> . Pandya, S. S. (C)	562
Cells, T,	
An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., <i>et al.</i> (A)	749
BCG-induced suppressor T cells optimal conditions for <i>in vitro</i> induction and mode of action. Mustafa, A. S. and Godal, T. (A)	187
Characteristics of human T-cell clones from BCG and killed <i>M. leprae</i> vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., <i>et al.</i> (A)	750
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., <i>et al.</i> (A)	595
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., <i>et al.</i> (A)	384
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., <i>et al.</i> (A)	743
<i>M. leprae</i> antigen-induced suppression of T cell proliferation <i>in vitro</i> . Kaplan, G., <i>et al.</i> (A)	596
Molecular localization and polymorphism of HLA class II restriction determinants defined by <i>M. leprae</i> -reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., <i>et al.</i> (A)	384
Possible role of helper and cytolytic T cells in mycobacterial infections. Kaufmann, S. H. E., <i>et al.</i> (A)	748

Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., <i>et al.</i> (A)	379
Reversal of T cell unresponsiveness in lepromatous leprosy. Nath, I. (A)	751
Study of DTH and resistance in <i>M. lepraemurium</i> infection using a T-cell line isolated from mice infected with <i>M. bovis</i> (BCG). Hussein, S., <i>et al.</i> (A)	595
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with <i>M. lepraemurium</i> . Richard, L., <i>et al.</i> (O)	63
T-cell defect in lepromatous leprosy is reversible <i>in vitro</i> in the absence of exogenous growth factors. Mohaghehpour, N., <i>et al.</i> (A)	383
T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., <i>et al.</i> (A)	610
The identification of T cell epitopes in <i>M. tuberculosis</i> using human T lymphocyte clones. Lamb, J. R., <i>et al.</i> (A)	749
Type 1 reactions in leprosy—heterogeneity in T-cell functions related to the background leprosy type. Laal, S., <i>et al.</i> (O)	481
Cell-mediated immunity (CMI),	
Deficiency of cell mediated immunity in leprosy. Gill, H. K. and Godal, T. (A)	177
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (O)	36
Is neopterin—a marker of cell mediated immune response—helpful in classifying leprosy? Schmutzhard, E., <i>et al.</i> (A)	599
Regulation of cell-mediated immunity in lepromatous leprosy. Kaplan, G. and Cohn, Z. A. (A)	747
T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. (A)	189
Chemotaxis,	
Defective monocyte chemotaxis in active lepromatous leprosy. Schuller-Levis, G., <i>et al.</i> (O)	267
Macrophage chemotaxis in <i>M. leprae</i> infected mice. Kumar, B., <i>et al.</i> (A)	597
Chemotherapy, (see also Therapy),	
A report on two follow-up investigations of the Malta Project. Jopling, W. H. (A)	582
Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) SWG of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (A)	588
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., <i>et al.</i> (A)	776
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., <i>et al.</i> (A)	739
Combined chemotherapy of multibacillary leprosy of 6 months' duration. Onsun, N., <i>et al.</i> (A)	585
Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. (A)	579
[Comparison of three therapeutic regimens for paucibacillary leprosy; preliminary note.] Huser, J. A., <i>et al.</i> (A)	739
Development of new chemotherapeutic agents in leprosy. Dhople, A. M., <i>et al.</i> (A)	778
Efficacy of different regimens in multibacillary leprosy. Pattyn, S. R. (A)	586
Limited duration acedapsona prophylaxis in leprosy. Neelan, P. N., <i>et al.</i> (A)	183
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. (A)	762
Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Grosset, J. (A)	581
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., <i>et al.</i> (A)	763
Short term chemotherapy of paucibacillary leprosy. Dhir, R., <i>et al.</i> (A)	579

Teaching video on chemotherapy of leprosy available.	(N)	736
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., <i>et al.</i>	(S)	807
The normal mouse in experimental chemotherapy. Levy, L.	(S)	843
[Treatment of 519 cases of leprosy with combined regimens.] Chen, D.	(A)	371
Workshop on Experimental Chemotherapy of Leprosy, Osaka, Japan, 11–20 November 1986.	(S)	797
China, People's Republic of,		
[Economic benefits of leprosy control.] Shu, H., <i>et al.</i>	(A)	370
[Effects of controlling leprosy in Wuhan City.] Lu, J.	(A)	392
[Epidemic of leprosy and its control in Guangdong.] Yang, X.	(A)	393
[Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] Cai, Z. and Hong, D.	(A)	392
[Epidemiological changes in Fujian Province, China.] Shao, K., <i>et al.</i>	(A)	605
[Formation and origin of leprophobia.] Lu, J.	(A)	394
National conference on MDT of leprosy held in Cheng-du. Ye, G.	(N)	363
Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China.	(B)	574
[Relapse of leprosy in Jinju hospital for old-disabled persons.] Liu, W.	(A)	740
Research work on social medicine of leprosy. Ye, G.-Y.	(N)	730
[Review of leprosy control in Jiangsu Province.] Ren, X. and Xie, Z.	(A)	393
[Survey of regular drug taking in leprosy patients in Guangdong.] Zeng, J., <i>et al.</i>	(A)	373
[Survey on leprosy in Henan Province.] Lei, G.	(A)	392
[Survey on leprosy in the Southwest Prefecture, Guizhou Province.] Zhou, T.	(A)	394
Chromatography,		
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of <i>M. leprae</i> . Kusaka, T. and Mori, T.	(A)	387
Cimetidine,		
Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., <i>et al.</i>	(C)	548
Dr. Nelson <i>et al.</i> 's response. Nelson, K. E.	(C)	551
Ciprofloxacin,		
Activities of pefloxacin and ciprofloxacin against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i>	(O)	70
<i>In vitro</i> susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C.	(A)	185
Clinic(s),		
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., <i>et al.</i>	(A)	583
Treatment clinics for Hansen's disease.	(N)	573
Clinical,		
[A case of delayed diagnosis of leprosy.] Bazurov, G. I.	(A)	375
Amniotic band syndrome. Pavithran, K.	(A)	175
[An etiology of anterior segment diseases not to be ignored: leprosy.] Travers, C., <i>et al.</i>	(A)	378
Anaesthetic complications in a leprosy patient. Sarate, G. S., <i>et al.</i>	(A)	591
Application of the mouse food-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L.	(S)	823
Certainty levels in the diagnosis of leprosy. Ponnighaus, J. M., <i>et al.</i>	(O)	454
[Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., <i>et al.</i>	(A)	739

- Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., *et al.* (C) 556
- Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. (A) 592
- [Clinical manifestations and biological perturbations in the course of erythema nodosum leprosum.] Daluz, W. (A) 376
- Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* (A) 374
- Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., *et al.* (A) 589
- Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* (O) 277
- Clinico-histopathological evaluation of modified piloarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., *et al.* (A) 376
- [Combined and supervised treatment of leprosy—two years of follow-up.] Ravettini, B. and Achenbach, R. (A) 587
- Hansen's disease following lymphoma. Levy, M. L., *et al.* (A) 376
- Hansen's disease (leprosy) revisited. Waroyar, B. and Adams, L. M. (A) 593
- Influence of environmental mycobacteria on the prevalence of leprosy clinical type. Lyons, N. F. and Naafs, B. (O) 637
- Isolation of a nocardia-like chemoautotroph from clinically proven multibacillary cases of leprosy. Chakrabarty, A. N., *et al.* (A) 755
- Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. (A) 762
- [Outpatient treatment of leprosy patients for 4 years in Luding County, Sichuan Province.] (China) Xiong, D., *et al.* (A) 760
- Pityriasis rubra pilaris with leprophobia. Pankajam, R., *et al.* (C) 555
- Semen analyses in Hansen's disease. Sheriff, D. S. (A) 592
- The biomechanics of the interphalangeal joints. Brand, P. W., *et al.* (A) 607
- The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. (S) 864
- Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., *et al.* (O) 441
- [Treatment of leprosy with human metabolites.] Mester de Parajd, L. and Mester de Parajd, M. (A) 584
- Clofazimine,**
- Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* (A) 584
- In vitro* activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Ausina, V., *et al.* (A) 607
- Pharmacokinetics of clofazimine in healthy volunteers. Schaad-Lanyi, Z., *et al.* (O) 9
- Response to Dr. Pfaltzgraff. Gelber, R. H. and Zacharia, A. G. (C) 554
- [Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., *et al.* (A) 372
- The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* (A) 373
- [Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* (A) 372
- [Three cases of multibacillary leprosy treated with B663 in four-drug regimen for one year.] Wang, Q. and Chen, J. (A) 373
- Complement,**
- Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A) 764
- Concanavalin A (ConA),**
- Phenolic glycolipid-1 of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* (A) 385
- Congresses,**
- Amsterdam will host 1988 International Congress for Tropical Medicine and Malaria. (N) 364

XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. (N)	731
The 13th International Leprosy Congress, tentative program. (N)	728
XII International Congress for Tropical Medicine and Malaria. (N)	571
Control of leprosy,	
Disability assessment as a measure of progress in leprosy control. Smith, W. C. S. and Parkhe, S. M. (A)	184
Dropouts during treatment for leprosy. (A study in the ELEP Leprosy Control Project, Dharmapuri District, Tamil Nadu, during 1975-1977). (India) Gopalakrishnan, S. ... (A)	371
[Economic benefits of leprosy control.] (China) Shu, H., <i>et al.</i> (A)	370
[Effects of controlling leprosy in Wuhan City.] (China) Lu, J. (A)	392
[Effects of leprosy control in Yulin Prefecture.] (China) Wang, C., <i>et al.</i> (A)	759
[Epidemic of leprosy and its control in Guangdong.] (China) Yang, X. (A)	393
[Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] (China) Cai, Z. and Hong, D. (A)	392
[Leprosy control in 30 years in Hechi Prefecture.] (China) Pan, R. (A)	759
[New plan of the war against leprosy in Anjouan; preliminary results.] Grillone, S. and Pattyn, S. R. (A)	739
Proceedings of the Inauguration of China Leprosy Association, China Leprosy Foundation, China Leprosy Control and Research Centre and the First International Leprosy Symposium in China. (B)	574
[Review of leprosy control in Jiangsu Province.] (China) Ren, X. and Xie, Z. (A)	393
Study of compliance of the patients in leprosy control programme in an urban slum. Kartikeyan, S. and Bhalerao, V. R. (A)	582
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. (A)	182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. (A)	183
Corticosteroids,	
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. (A)	176
Reversal reaction—management with tropical corticosteroids. Srinivas, C. R., <i>et al.</i> ... (C)	355
Cuba,	
Survey for primary dapsone resistance in Cuba. Gonzalez, A. B., <i>et al.</i> (A)	371
Cultivation,	
Cultivable mycobacteria isolated from 32 newly captured armadillos (<i>Dasypus novemcinctus</i>) from Louisiana. (U.S.A.) Portaels, F., <i>et al.</i> (A)	788
[Cultivation of tubercle and opportunistic mycobacteria on medium with <i>N</i> -alkanes.] Koronelli, T. V. and Fadeeva, N. I. (A)	763
Investigations into cultivation of <i>M. leprae</i> in a nasal mucus medium: a preliminary report. Prabhakar, M. C. (C)	561
Investigations into the cultivation of <i>M. leprae</i> ; a multifactorial approach. Kato, L. ... (A)	602
Studies of <i>in vitro</i> -cultivated isolates of <i>M. leprae</i> from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. (A)	405
Cutaneous,	
Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., <i>et al.</i> (A)	761
Hansen's disease: a new endemic focus in the Piacenza Province (Italy)? A description of four diagnosed cases by cutaneous biopsy. Paties, C., <i>et al.</i> (A)	393
[Study of new method for the application of tuberculin ointment for cutaneous use in comparison with the Mantoux test.] Levi, D. T., <i>et al.</i> (A)	763
Cyclosporine,	
Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., <i>et al.</i> (A)	386
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., <i>et al.</i> (O)	441

Dapsone (DDS),

- A Spot Test for Dapsone in Urine* by Han Huikeshoven. Hastings, R. C. (B) 574
- Association between regularity in dapsone (DDS) treatment and development of deformity. Radhakrishna, S. and Nair, N. G. K. (O) 425
- Binding of dapsone and its analogues to human serum albumin. Karp, W. B., *et al.* . . (A) 172
- Blood dapsone levels in leprosy patients treated with acedapsone. George, J. and Balakrishnan, S. (A) 371
- Clinical pharmacokinetics of dapsone. Zuidema, J., *et al.* (A) 374
- Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. (A) 579
- Dapsone dependent nodular panniculitis. Uplekar, M. W. and Antia, N. H. (A) 173
- Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., *et al.* (A) 761
- Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., *et al.* (O) 23
- Dapsone resistance in *M. leprae*: a genotypic change. Prabhakaran, K., *et al.* (A) 181
- Dapsone susceptibility of *M. leprae* before and after 1977. Almeida, J. G. (C) 726
- Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Seville, A., *et al.* (O) 16
- Dapsone-induced peripheral neuropathy. Ahrens, E. M., *et al.* (A) 607
- Diabetogenic effect of dapsone. Asensio, A. S., *et al.* (C) 357
- Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* (A) 584
- ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme. Greenwood, B. M., *et al.* (A) 580
- [Intramuscular administration of dapsone in leprosy: a new approach.] Modderman, E. S. M. (A) 585
- Methemoglobinemia from dapsone therapy for a suspected brown spider bite. Iserson, K. V. (A) 581
- Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* (A) 372
- Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* (O) 672
- [Report on four cases with acute DDS intoxication.] Wang, Z. and Chen, J. (A) 740
- [Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S. (A) 374
- [Study on DDS resistance using the mouse foot pad technique.] Liu, X and Lin, Z. . . (A) 757
- Survey for primary dapsone resistance in Cuba. Gonzalez, A. B., *et al.* (A) 371
- Sustained-release delivery systems, I: Phase diagram studies of dapsone and selected derivatives. Yang, T.-T. and Swarbrick, J. (A) 741
- Sustained-release delivery systems, II: *In vitro* dissolution of 4, 4'-sulfonylbisbenzamine (dapsone)—*N*-dodecanoyl-4, 4'-sulfonylbisbenzamine comelts. Yang, T.-T. and Swarbrick, J. (A) 741
- The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* (A) 373
- The killing of *M. leprae* in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. (A) 390
- [Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* (A) 372
- [Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. (A) 374

Deformity(ies),

- Association between regularity in dapsone (DDS) treatment and development of deformity. Radhakrishna, S. and Nair, N. G. K. (O) 425
- [Loss of labor ability and social economics from leprosy deformities.] Shu, W., *et al.* . . (A) 761
- [Psychosis of leprosy patients from social discrimination and somatic deformities.] Pan, X., *et al.* (A) 760

Dermal,

- An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and Chacko, C. J. G. (O) 515
- Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., *et al.* (A) 416

Dermatoglyphics,

- An evaluation of palmar flexion creases and dermatoglyphics in leprosy. Gupta, C. M. and Tutakne, M. A. (A) 174
- [Asymmetry of dermatoglyphical indices and topics of tuberculosis process in the lungs.] Zosimov, A. N. and Khodzitskaya, V. K. (A) 766

Dermatology,

- 80th anniversary of Asociación Argentina de Dermatología. (N) 363
- XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. (N) 731
- Samuel Patton Impey, M. D. (Aberdeen) (1856–1928), Cape Town's primordial leprologist, dermatologist, radiotherapist and rock-art enthusiast. Findlay, G. H. (A) 738

DNA,

- Cloning and expression of mycobacterial plasmid DNA in *Escherichia coli*. Labidi, A., *et al.* (A) 186
- Genetic relatedness among strains of the *M. tuberculosis* complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., *et al.* (A) 608
- Isolation and restriction endonuclease analysis of mycobacterial DNA. Patel, R., *et al.* (A) 609
- Use of recombinant DNA molecules in epidemiological studies of leprosy. Clark-Curtiss, J. E., *et al.* (A) 788

Drugs (see also specific drugs),

- Activities of pefloxacin and ciprofloxacin against *M. leprae* in the mouse. Guelpa-Lauras, C.-C., *et al.* (O) 70
- An *in vitro* system using adenosine triphosphate and ³H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. (A) 172
- Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. (S) 823
- Binding of dapson and its analogues to human serum albumin. Karp, W. B., *et al.* (A) 172
- Blood dapson levels in leprosy patients treated with acedapson. George, J. and Balakrishnan, S. (A) 371
- Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* (C) 548
- [Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* (A) 739
- Clinical pharmacokinetics of dapson. Zuidema, J., *et al.* (A) 374
- Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study. Dietrich, M. and Wabitsch, R. (A) 579
- Dapson dependent nodular panniculitis. Uplekar, M. W. and Antia, N. H. (A) 173
- Drug susceptibility testing of *M. leprae*. Ji, B. (S) 830
- Effect of clofazimine and dapson on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., *et al.* (A) 584
- Effect of combined clofazimine and ansamycin therapy on *M. avium-M. intracellulare* bacteremia in patients with AIDS. Masur, H., *et al.* (A) 396
- Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., *et al.* (A) 386
- Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., *et al.* (A) 739
- Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Kar, H. K., *et al.* (A) 582
- Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., *et al.* (A) 604
- [Hepatotoxicity of ethionamide—a current problem.] See, A., *et al.* (A) 373
- Host-pathogen interaction—new *in vitro* drug test systems against *M. leprae*; possibilities and limitations. Mahadevan, P. R., *et al.* (A) 583

- Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy. Balakrishnan, S., *et al.* (A) 577
- In vitro* susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C. (A) 185
- [Laboratory studies on antituberculous activity of cyclopentylrifampicin. II. A long-acting antituberculous cyclopentylrifampicin.] Pan, Y., *et al.* (A) 187
- [II. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* (A) 742
- Metabolic analyses of *M. leprae*: use in evaluation of *in vitro* culture media and drug activity. Franzblau, S. G. and Harris, E. B. (A) 402
- Metabolism in *M. leprae*: possible targets for drug interaction. Wheeler, P. R. (A) 589
- Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. (A) 414
- Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., *et al.* (A) 372
- Pharmacokinetics in drug screening. Grosset, J. H. (S) 852
- Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. (A) 581
- Psychosocial dimensions of drug default in leprosy. Anandaraj, H. (A) 375
- Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy.* (B) 737
- Rifabutin and rifapentine compared with rifampin against *M. leprae* in mice. Pattyn, S. R. (A) 373
- Screening of drugs for activity against *M. leprae*. Ji, B., *et al.* (S) 836
- [Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., *et al.* (A) 372
- Side effects of levamisole. Arora, S. K., *et al.* (A) 577
- [Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S. (A) 374
- Strategies in the development of new drugs and drug combinations against leprosy, demonstrated on the example of folate and gyrase inhibitors. Seydel, J. K., *et al.* (A) 588
- [Survey of regular drug taking in leprosy patients in Guangdong.] (China) Zeng, J., *et al.* (A) 373
- Thalidomide in leprosy—study of 94 cases. Parikh, D. A., *et al.* (A) 585
- [Thalidomide induced neuropathy.] Chapon, F., *et al.* (A) 579
- The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., *et al.* (A) 373
- The Malta experience: isoprodian-rifampicin combination treatment for leprosy. DePasquale, G. (A) 579
- The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. (S) 864
- [Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., *et al.* (A) 372
- [Three cases of multibacillary leprosy treated with B663 in four-drug regimen for one year.] Wang, Q. and Chen, J. (A) 373
- [Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. (A) 374
- Update on rifampin drug interactions. Baciewicz, A. M., *et al.* (A) 577
- Electron microscopy, (see also Ultrastructure),**
- Electron microscopic study of the intracellular fate of *M. leprae* in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. (A) 411
- ELISA (enzyme-linked immunosorbent assay) tests,**
- A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* (A) 178
- Development of a dot-ELISA for detection of leprosy antigenuria under field conditions. Kaldany R.-R. J. and Nurlign, A. (A) 747
- ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme. Greenwood, B. M., *et al.* (A) 580

Enzymes,

- Enzymes and other biochemically active components of mycobacteria. Draper, P. (A) 755

Epidemiology,

- A molecular approach to epidemiological studies of leprosy. Clark-Curtiss, J. E. (A) 405
 [Comprehensive study of household gathering of leprosy with probability model of negative binomial and Poisson distributions.] Jiang, C., *et al.* (A) 758
 Environmental nonhuman sources of leprosy. Blake, L. A., *et al.* (A) 758
 [Epidemic of leprosy and its control in Guangdong.] (China) Yang, X. (A) 393
 [Epidemic of leprosy and the effect of its control in the South Prefecture, Jiangxi Province.] (China) Cai, Z. and Hong, D. (A) 392
 [Epidemic state of leprosy in Shannan Prefecture of Tibet.] Wei, A. (A) 759
 [Epidemiological changes in Fujian Province, China.] Shao, K., *et al.* (A) 605
 [Epidemiological profile of leprosy in Algeria.] Oughanem, M., *et al.* (A) 393
 [Epidemiological survey of leprosy in Ankang Prefecture, Shanxi Province.] Hu, Y., *et al.* (A) 758
 Genetic epidemiology of the susceptibility to leprosy. Shields, E. D., *et al.* (A) 606
 Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., *et al.* (O) 88
 [Investigation and analysis of leprosy epidemiology in Lufeng County of Guangdong Province.] Wang, Q., *et al.* (A) 759
 [Investigation of leprosy endemic foci in Nandan County.] Lu, Z., *et al.* (A) 759
 On the epidemiology of leprosy in Malta. Leiker, D. L. (A) 583
 Retrieval of "left the area leprosy cases" by cross-notification. Rao, P. S. (A) 393
 Social and demographic aspects of a leprosy epidemic on a Polynesian atoll: implications of pattern. Lieber, M. D. and Lieber, E. B. (O) 468
 [Survey of leprosy in Dali Bai Autonomous Prefecture, Yunnan.] Du, J. (A) 758
 [The epidemiology of leprosy.] Diop Mar, I., *et al.* (A) 605
 [The epidemiology of leprosy in Guadeloupe from 1970 to 1984.] Cartel, J.-L., *et al.* ... (A) 392
 Use of recombinant DNA molecules in epidemiological studies of leprosy. Clark-Curtiss, J. E., *et al.* (A) 788

Erythema nodosum leprosum (ENL),

- Attempts to produce erythema nodosum leprosum in *M. leprae*-infected nude nu/nu mice with monoclonal antibodies. Chehl, S., *et al.* (A) 410
 [Clinical manifestations and biological perturbations in the course of erythema nodosum leprosum.] Daluz, W. (A) 376
 Effect of cyclosporine A in erythema nodosum leprosum. Uyemura, K., *et al.* (A) 386
 Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (O) 36
 [Erythema nodosum leprosum with necrotic development.] Husser, J. A., *et al.* (A) 376
 Plasma exchange in severe erythema nodosum leprosum. Wallach, D., *et al.* (A) 592
 T γ , T μ and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (A) 599
 The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., *et al.* (A) 179
 Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. Miller, R. A., *et al.* (O) 441

Ethionamide,

- [Hepatotoxicity of ethionamide—a current problem.] See, A., *et al.* (A) 373
 Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. (A) 581

Ethiopia,

- Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* (C) 548
 HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* (O) 261
 Operational aspects of implementation of multidrug therapy at ALERT, Ethiopia. Becx-Bleumink, M. (A) 578

- Experimental leprosy,**
 Effect of ofloxacin on experimental leprosy. Ito, T., *et al.* (A) 778
 Experimental leprosy in a rhesus monkey: necropsy findings. Baskin, G. B., *et al.* (O) 109
 Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* (A) 751
M. leprae-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* (A) 417
 Multiplication of *M. leprae* in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., *et al.* (S) 889
 Sciatic nerve in experimental leprosy. Vaishnavi, C., *et al.* (A) 391
 The search for animal models of leprosy. Johnstone, P. A. S. (E) 535
- Eye(s),**
 Anterior leptotic retinitis of trantans; a case report. Singh, M. (A) 176
 [Effects of orthopedic and conservative therapies on paralytic lagophthalmus.] Chen, Q. and Jing, X. (A) 760
 Factors influencing corneal involvement in leprosy. Lamba, P. A., *et al.* (O) 667
 Ocular leprosy: a case report and discussion of the pathology. House, P. H. (A) 174
 Study of hydration of stratum corneum in leprosy. Okhandiar, R. P., *et al.* (A) 377
 [Survey of eye diseases in 527 leprosy patients.] Li, S. and Fu, Q. (A) 377
 Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., *et al.* (O) 507
 Uveal changes in leprosy. Rohatgi, J., *et al.* (A) 175
- Family(ies),**
 An investigation of family size and birth order as risk factors in leprosy. Koumantaki, I. G., *et al.* (O) 463
 Family studies of leprosy cases. Guha, P. K., *et al.* (A) 182, 590
- FLA-ABS test,**
 Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations. Amezcua, M. E., *et al.* (O) 286
- Foot,**
 A standard dorsal-plantar and lateral radiographic projections of the feet. Brand, P. W. and Coleman, W. C. (A) 607
 Effect of rocker sole design on plantar forefoot pressures. Nawoczinski, D., *et al.* (A) 415
 Foot pressure measurement in leprosy and footwear designs. Patil, K. M., *et al.* (A) 395
 Hansen's disease with pedal involvement; a case report. Ottinger, M. L. and Black, J. R. (A) 175
 Microflora in the trophic ulcers of the foot in leprosy. Chatterjee, B. D., *et al.* (A) 375
 Plantar sensory threshold in the ulcerative foot. Birke, J. A. and Sims, D. S. (A) 184
 The insensitive foot; Northwick Park experience. Geary, N. P. J. and Klenerman, L. ... (A) 606
- Foot pad(s),**
 Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. (S) 823
 [Study on DDS resistance using the mouse foot pad technique.] Liu, X. and Lin, Z. ... (A) 757
 The effect of diet on the growth of *M. leprae* in mouse foot pads. Foster, R., *et al.* (A) 403
- France,**
 Primary and secondary dapson resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* (O) 672
- Genetics,**
 Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. leprae-murium*. Hoffenbach, A. and Bach, M.-A. (A) 390
 [Genetic component of the immune response to *M. leprae* in healthy individuals.] Bottasso, O. A., *et al.* (A) 593
 Genetic epidemiology of the susceptibility to leprosy. Shields, E. D., *et al.* (A) 606

Genetic relatedness among strains of the <i>M. tuberculosis</i> complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., <i>et al.</i> (A)	608
The "Hansen-aneergic fringe." Rotberg, A. (A)	599
Germany,	
Foundation of the Hansen Institute, Wurzburg. (N)	363
Granuloma(s),	
Accessory cell function of cells isolated from <i>M. leprae</i> -induced granulomas. Montreewasuwat, N., <i>et al.</i> (A)	383
Characterization of CD4-positive T-lymphocyte subsets in leprosy granulomas. Rea, T. H. and Modlin, R. L. (A)	786
Elastase activity in granulomatous inflammation in experimental murine leprosy. Hsu, P.-S., <i>et al.</i> (A)	381
Granulomatous inflammation in the acquired immune deficiency syndrome. Jagadha, V., <i>et al.</i> (A)	186
Guadeloupe,	
Primary and secondary dapsone resistance of <i>M. leprae</i> in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	672
[The epidemiology of leprosy in Guadeloupe from 1970 to 1984.] Cartel, J. L., <i>et al.</i> . . (A)	392
Hand(s),	
A study of palmar ridge malformation in leprosy. Gupta, C. M., <i>et al.</i> (A)	590
Simplified surgical technique for flexible clawed hand rehabilitation. Chevillard, A. J. (C)	160
The repeatability of testing with Semmes-Weinstein monofilaments. Bell-Krotoski, J. and Tomancik, E. (A)	394
Heiser Program, The,	
The Heiser Program for Research in Leprosy 1988. (N)	572
Histology,	
A rapid silver staining method for identification of <i>M. leprae</i> in histologic sections. Senba, M., <i>et al.</i> (A)	599
[Histologic evolution of paucibacillary leprosy during treatment with various therapeutic regimens.] Pattyn, S. R., <i>et al.</i> (A)	587
Rationale for the histological spectrum of tuberculosis; a basis for classification. Ridley, D. S. and Ridley, M. J. (A)	764
Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., <i>et al.</i> (O)	507
Histopathology,	
[A study of the histopathologic changes of the nasal mucosa in patients with leprosy.] Kim, H. B. and Kim, M. Y. (A)	596
Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., <i>et al.</i> (C)	556
Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. (A)	592
Clinico-histopathological evaluation of modified piloarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., <i>et al.</i> (A)	376
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., <i>et al.</i> (O)	88
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. Fleury, R. N. and Bacchi, C. E. (O)	338
The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., <i>et al.</i> (A)	179
Venous involvement in leprosy: a venographic and histopathological correlation. Bansal, R., <i>et al.</i> (O)	499
History of leprosy,	
Early tractata on leprosy. Kato, L. (C)	157
Plague and leprosy in the Middle Ages: a paradoxical cross-immunity? Ell, S. R. (E)	345
. (A)	401

HLA,

- An HLA-DR3 immune response gene for *M. leprae* predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. (A) 779
- An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., *et al.* (A) 749
- Evidence for an HLA-DR4-associated immune-response gene for *M. tuberculosis*. Ottenhoff, T. H. M., *et al.* (A) 609
- HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* (O) 261
- HLA class II immune response and suppression genes in leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. (R) 521
- HLA class II restricted helper and suppressor clones reactive with *M. leprae*. de Vries, R. R. P., *et al.* (A) 745
- Molecular localization and polymorphism of HLA class II restriction determinants defined by *M. leprae*-reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., *et al.* (A) 384
- The HLA antigens and leprosy in Korea. Kim, S. J., *et al.* (A) 183

Hypersensitivity,

- Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae*, *M. tuberculosis*, *M. vaccae*, and *M. bovis* (BCG). Sinha, S., *et al.* (O) 42
- Delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine. (A) 593
- Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., *et al.* (A) 595
- Etiological factors in delayed-type hypersensitivity reactions in leprosy. Klenerman, P. (E) 702
- Influence of delayed immune reactions on human epidermal keratinocytes. Kaplan, G., *et al.* (A) 178
- Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* (A) 595
- Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* (A) 600
- Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium*. Richard, L., *et al.* (O) 63
- The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., *et al.* (A) 745
- The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorobenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., *et al.* (A) 610
- The role of IFN-gamma in the regulation of DTH in human skin. Kaplan, G. and Cohn, Z. A. (A) 785

ICRC bacilli,

- Effects of ICRC antileprosy vaccine in healthy subjects. Chaturvedi, R. M., *et al.* (O) 657

IgA,

- [Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* (A) 378

IgG,

- The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiée, R., *et al.* (A) 419

IgM,

- A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* (A) 178
- [Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* (A) 378
- The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with *M. leprae*. Vadiée, R., *et al.* (A) 419

ILEP,		
ILEP Catalogue on Training, 1987.(N)		734
XVI General Assembly of ILEP, Edinburgh, July 1986.(N)		168
Immune complexes,		
Circulating immune complexes in normal and immunosuppressed mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i>(A)		604
[Detection of immune complexes in lepromatous leprosy. I. Appraisal of precipitation technique with polyethylene glycol.] Valdes-Portela, A.(A)		592
Effect of preformed immune complexes on the course of <i>M. leprae</i> infection in normal mice. Kaur, S., <i>et al.</i>(C)		358
Immune responses,		
Distribution and turnover of Langerhans cells during delayed immune responses in human skin. Kaplan, G., <i>et al.</i>(A)		748
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R.(O)		36
Humoral immune responses to <i>M. leprae</i> in human volunteers vaccinated with killed, armadillo-derived <i>M. leprae</i> . Gill, H. K., <i>et al.</i>(A)		746
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of <i>M. leprae</i> and BCG. Rada, E. M., <i>et al.</i>(O)		646
Immunoglobulins,		
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., <i>et al.</i>(O)		277
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., <i>et al.</i>(A)		378
Immunology,		
An unusual case of untreated lepromatous leprosy with rare bacilli: an immunologic follow-up. Gelber, R. H. and Mohaghehpour, N.(C)		353
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L.(S)		823
Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J.(A)		600
Immunologic aspects of leprosy. Ashmalla, L.(A)		590
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G.(A)		746
Indo-U.S. Symposium on Immunology & Molecular Biology of Leprosy.(N)		165
[Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., <i>et al.</i>(A)		763
The immunobiology of leprosy. Kaplan, G. and Cohn, Z. A.(A)		177
Immunoperoxidase,		
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. Fleury, R. N. and Bacchi, C. E.(O)		338
Immunosuppression,		
A possible role for E-receptor in immunosuppression in leprosy. Muthukkaruppan, V. R.(A)		383
ADCC function in <i>M. leprae</i> inoculated normal and immunosuppressed mice. Ganguly, N. K., <i>et al.</i>(A)		390
Circulating immune complexes in normal and immunosuppressed mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i>(A)		604
Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of <i>M. leprae</i> and BCG. Rada, E. M., <i>et al.</i>(O)		646
Immunotherapy,		
Immunotherapy in leprosy: a new approach. Chattopadhyay, S. P. and Gupta, C. M.(A)		173
India,		
A preliminary report on <i>M. leprae</i> in Aurangabad. Kalyankar, S. D., <i>et al.</i>(A)		605
Bombay Acworth Seminars 1985-1986.(N)		363

Dr. Ganapati's leprosy studies recognized. Maniar, J. K.	(N)	570
Dr. Thangaraj and Mr. Askew retire.	(N)	730
Dropouts during treatment for leprosy. (A study in the ELEP Leprosy Control Project, Dharmapuri District, Tamil Nadu, during 1975–1977). Gopalakrishnan, S.	(A)	371
IAL workshop held.	(N)	570
Indo-U.S. Symposium on Immunology & Molecular Biology of Leprosy.	(N)	165
International Meeting on Voluntary Organizations in Leprosy.	(N)	167
KLEP: Karigiri Leprosy Education Programme, South India.	(N)	730
Leprosy in eastern region of Rajasthan. Mishra, B., <i>et al.</i>	(A)	605
Mass vaccination studies initiated.	(N)	364
New Director-General of Indian Council of Medical Research.	(N)	570
1987 National Awards for the Welfare of the Handicapped.	(N)	730
Premananda Memorial Leprosy Hospital opened.	(N)	364
<i>Studies on Leprosy in Bombay</i> . Hastings, R. C.	(B)	170
Study of autoantibodies in lepromatous leprosy in rural central India. Jain, A. P., <i>et al.</i>	(A)	175, 590
Western Regional Leprosy Workers' Conference.	(N)	167

Inoculation,

ADCC function in <i>M. leprae</i> inoculated normal and immunosuppressed mice. Ganguly, N. K., <i>et al.</i>	(A)	390
Detection of persisting <i>M. leprae</i> by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L.	(S)	872
Influence of route of inoculation on anti- <i>M. lepraemurium</i> antibody isotopes in murine leprosy. Hoffenbach, A., <i>et al.</i>	(O)	305
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoc- ulated with <i>M. leprae</i> . Vadiee, R., <i>et al.</i>	(A)	419

Interferon,

A single cell assay for the study of γ -interferon formation in leprosy patients. Lindh, J., <i>et al.</i>	(A)	382
Gamma interferon activates human macrophages to become tumoricidal and leish- manicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., <i>et al.</i>	(A)	186
Interferon-gamma induces the expression of major histocompatibility complex antigens by <i>in vitro</i> cultured murine Schwann cells. Mshana, R. N., <i>et al.</i>	(A)	781
<i>M. leprae</i> -burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L.	(A)	386
Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., <i>et al.</i>	(O)	651
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., <i>et al.</i>	(A)	763

Interleukin(s),

Assessment of the immune deficit in leprosy patients and the effect of recombinant IL-2 <i>in vitro</i> . Lochniskar, M., <i>et al.</i>	(O)	249
Bacillary growth, interleukin-2 production defect, and specific antibody secretion gov- erned by different genetical factors in mice infected subcutaneously with <i>M. leprae</i> - <i>murium</i> . Hoffenbach, A. and Bach, M.-A.	(A)	390
Deficiency in the biosynthesis of interleukin 2 (IL-2) and functional presence of the IL-2 receptor in lepromatous leprosy. Islas-Rodriguez, A. E., <i>et al.</i>	(C)	566
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein anti- gens. Wallis, R. S., <i>et al.</i>	(A)	188
Effect of interleukin-1 (IL-1) and IL-2 on lymphocytes from patients with leprosy. Rada, E. M., <i>et al.</i>	(C)	351
Leprosin stimulates interleukin-2 production and interleukin-2 receptor expression <i>in</i> <i>situ</i> in lepromatous leprosy patients. Longley, B. J., <i>et al.</i>	(A)	750
Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., <i>et al.</i>	(A)	379
Soluble serum interleukin 2 receptor levels in leprosy patients. Tung, K. S. K., <i>et al.</i> ..	(A)	753

INTERNATIONAL JOURNAL OF LEPROSY,		
Author Index to Volume 54—1986.	(—)	191
Reviewers.	(—)	792
Statement of financial condition.	(—)	611
Statement of ownership, management, and circulation.	(—)	795
Subject Index to Volume 54—1986.	(—)	202
The 1986 JOURNAL—a continuing perspective. Hastings, R. C.	(—)	140
International Leprosy Association,		
Officers and Councillors.	(—)	793
International Leprosy Congress,		
The 13th International Leprosy Congress, tentative program.	(—)	728
Intestine,		
[Small intestine transit anomalies in a patient with chronic abdominal pain and treated for leprosy.] Davy, C., <i>et al.</i>	(A)	371
Isoniazid,		
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., <i>et al.</i>	(A)	763
Italy,		
Hansen's disease: a new endemic focus in the Piacenza Province? A description of four diagnosed cases by cutaneous biopsy. Paties, C., <i>et al.</i>	(A)	393
Japan,		
<i>Research Activities of the National Institute for Leprosy Research. Special Issue for the 30th Anniversary.</i> Abe, M., ed.	(B)	170
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., <i>et al.</i>	(S)	807
Twenty-Second Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A., 20–22 July 1987. (U.S.–Japan Cooperative Medical Science Program).	(—)	767
Workshop on Experimental Chemotherapy of Leprosy, Osaka, Japan, 11–20 November 1986.	(S)	797
Kidney(s),		
Histo-functional status of kidney in leprosy. Nigam, P., <i>et al.</i>	(A)	591
Korea,		
The HLA antigens and leprosy in Korea. Kim, S. J., <i>et al.</i>	(A)	183
Leishmaniasis,		
Dapsone in the treatment of cutaneous leishmaniasis. Doga, J., <i>et al.</i>	(A)	761
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., <i>et al.</i>	(A)	186
Leonard Wood Memorial,		
Leonard Wood Memorial (LWM) seeking Director of Scientific Facility.	(N)	571
LWM course offered at Cebu.	(N)	365
Lepromatous leprosy,		
An HLA-linked gene controls susceptibility to lepromatous leprosy through T cell regulation. Kikuchi, I., <i>et al.</i>	(A)	749
An unusual case of untreated lepromatous leprosy with rare bacilli: an immunologic follow-up. Gelber, R. H. and Mohaghehpour, N.	(C)	353
Antigens of <i>M. leprae</i> in urine during treatment of patients with lepromatous leprosy. Olcén, P., <i>et al.</i>	(A)	384
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L.	(S)	823
Bilateral ulnar nerve abscesses in lepromatous leprosy. Pfaltzgraff, R. E.	(C)	553
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., <i>et al.</i>	(A)	776

Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., <i>et al.</i> (C)	548
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Nail, S., <i>et al.</i> (O)	273
Defective macrophage effector function in lepromatous leprosy. Krahenbuhl, J. L., <i>et al.</i> (A)	782
Defective monocyte chemotaxis in active lepromatous leprosy. Schuller-Levis, G., <i>et al.</i> (O)	267
Deficiency in the biosynthesis of interleukin 2 (IL-2) and functional presence of the IL-2 receptor in lepromatous leprosy. Islas-Rodriguez, A. E., <i>et al.</i> (C)	566
[Detection of immune complexes in lepromatous leprosy. I. Appraisal of precipitation technique with polyethylene glycol.] Valdes-Portela, A. (A)	592
Dr. Nelson <i>et al.</i> 's response. Nelson, E. E., <i>et al.</i> (C)	551
Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., <i>et al.</i> . . (A)	739
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., <i>et al.</i> (A)	378
Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Kar, H. K., <i>et al.</i> (A)	582
Lepromatous leprosy. Miller, J. A., <i>et al.</i> (A)	175
Lepromin stimulates interleukin-2 production and interleukin-2 receptor expression <i>in situ</i> in lepromatous leprosy patients. Longley, B. J., <i>et al.</i> (A)	750
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., <i>et al.</i> (A)	384
Lymphocyte transformation in lepromatous leprosy: a study of the influence of disease activity and symptom duration. Brown, A. E., <i>et al.</i> (A)	379
Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., <i>et al.</i> (O)	333
Oral lesions in lepromatous leprosy. Bucci, F., Jr., <i>et al.</i> (A)	742
Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T-cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin. Barnass, S., <i>et al.</i> (A)	379
Primary visceral Virchowian (lepromatous) hanseniasis. Azulay, R. D. (O)	450
Regulation of cell-mediated immunity in lepromatous leprosy. Kaplan, G. and Cohn, Z. A. (A)	747
Response to Dr. Pfaltzgraf. Gelber, R. H. and Zacharia, A. G. (C)	554
Reversal of T cell unresponsiveness in lepromatous leprosy. Nath, I. (A)	751
Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, The Philippines. Douglas, J. T., <i>et al.</i> (C)	718
Significant enhanced superoxide anion (O ₂) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., <i>et al.</i> (A)	746
Studies of <i>in vitro</i> -cultivated isolates of <i>M. leprae</i> from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. (A)	405
Study of autoantibodies in lepromatous leprosy in rural central India. Jain, A. P., <i>et al.</i> (A)	175, 590
Suppression of delayed hypersensitivity skin reactions to tuberculin by <i>M. leprae</i> antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., <i>et al.</i> (A)	600
Suppressor response in lepromatous leprosy patients: role of Leu2a cells. Sasiain, M. del C., <i>et al.</i> (A)	385
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	179
T cell defect in lepromatous leprosy is reversible <i>in vitro</i> in the absence of exogenous growth factors. Mohaghehpour, N., <i>et al.</i> (A)	383
Tetanus in a case of lepromatous leprosy. Parikh, A. A. and Shah, B. H. (A)	591
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., <i>et al.</i> (A)	754
Ultrasonographic findings in the livers of patients with lepromatous leprosy. Doehring, E., <i>et al.</i> (A)	173
Undernutrition in lepromatous leprosy, Part I. Is it associated with poverty or with disease? Rao, K. N., <i>et al.</i> (A)	377
Undernutrition in lepromatous leprosy, Part II. Altered levels of serum elements; their	

association with the disease and not with food deprivation. Rao, K. N. and Saha, K. (A)	377
Lepromin,	
[Behavior of the intradermal reaction with lepromin in patients with sarcoidosis.] Gu- maraes Proenca, N., <i>et al.</i> (A)	177
Immunohistologic comparison between armadillo-derived leprosin and standard lep- romin skin tests in leprosy patients. Narayanan, R. B., <i>et al.</i> (A)	598
Lepromin stimulates interleukin-2 production and interleukin-2 receptor expression <i>in</i> <i>situ</i> in lepromatous leprosy patients. Longley, B. J., <i>et al.</i> (A)	750
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: reg- ulatory role of monocyte and lymphocyte subsets. Ohkawa, S., <i>et al.</i> (A)	751
Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., <i>et al.</i> (A)	384
Lesions,	
[Differential diagnosis of leprous lesions in Africans.] Akimov, V. G. (A)	375
Histochemical demonstration of mycobacterial antigen, specific antibody and comple- ment in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A)	764
[<i>In situ</i> characterization of immune cells in the annular lesions of leprosy.] Lee, C. W., <i>et al.</i> (A)	597
<i>In situ</i> identification of activated Ta1+ T lymphocytes in human leprosy skin lesions. Shen, J.-Y., <i>et al.</i> (O)	494
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. (A)	407
Oral lesions in lepromatous leprosy. Bucci, F., Jr., <i>et al.</i> (A)	742
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	179
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., <i>et al.</i> (A)	754
T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	750
Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A., <i>et al.</i> (A)	416
Unusual histological lesions in the eye of a leprosy patient. Zhou, H.-M., <i>et al.</i> (O)	507
Levamisole,	
Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous lep- rosy. Kar, H. K., <i>et al.</i> (A)	582
Side effects of levamisole. Arora, S. K., <i>et al.</i> (A)	577
Lipid,	
Lipid composition of human leprous tissue. Kumar, B., <i>et al.</i> (C)	162
Liver,	
Ultrasonographic findings in the livers of patients with lepromatous leprosy. Doehring, E., <i>et al.</i> (A)	173
Lucio leprosy,	
Specific antigen and antibody to <i>M. leprae</i> in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., <i>et al.</i> (A)	594
Lymph node(s),	
Metastasis of malignant plantar ulcer in lymph nodes in femoral triangle—a case report. Bobhate, S. K., <i>et al.</i> (A)	590
Lymphocyte(s),	
Arthritis induced by a T-lymphocyte clone that responds to <i>M. tuberculosis</i> and to cartilage proteoglycans. van Eden, W., <i>et al.</i> (A)	188
Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stim- ulated normal human lymphocytes. Kerr, M. A., <i>et al.</i> (A)	748
Characterization of CD4-positive T-lymphocyte subsets in leprosy granulomas. Rea, T. H. and Modlin, R. L. (A)	786
Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., <i>et al.</i> (O)	273

- Effect of interleukin-1 (IL-1) and IL-2 on lymphocytes from patients with leprosy. Rada, E. M., *et al.* (C) 351
- In situ* identification of activated T_H1 + T lymphocytes in human leprosy skin lesions. Shen, J.-Y., *et al.* (O) 494
- In vitro* proliferation of lymphocytes from human volunteers vaccinated with armadillo-derived, killed *M. leprae*. Gill, H. K., *et al.* (O) 30
- Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* (A) 751
- Lymphocyte transformation in lepromatous leprosy: a study of the influence of disease activity and symptom duration. Brown, A. E., *et al.* (A) 379
- M. leprae*-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* (A) 417
- M. leprae*-specific Lyt-2+ T lymphocytes with cytolytic activity. Chiplunkar, S., *et al.* (A) 380
- Quantitative analysis of contrasuppressor T lymphocytes in leprosy; induction of Ia antigens with gamma interferon. Gonzalez-Amaro, R., *et al.* (O) 651
- Regulatory role of FcR+ and FcR- monocyte subsets in *M. leprae*-induced lymphoproliferative response *in vitro*. Ohkawa, S., *et al.* (A) 384
- [Regulatory subpopulations of T lymphocytes in patients with pulmonary tuberculosis.] Averbakh, M. M., *et al.* (A) 761
- [Rosette-forming T lymphocytes of different types in patients with pulmonary tuberculosis.] Petrashenko, A. I. (A) 764
- Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* (A) 179
- T lymphocytes respond to solid-phase antigen: a novel approach to the molecular analysis of cellular immunity. Young, D. B. and Lamb, J. R. (A) 189
- T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., *et al.* (A) 750
- T_H1, T_H2 and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (A) 599
- The identification of T cell epitopes in *M. tuberculosis* using human T lymphocyte clones. Lamb, J. R., *et al.* (A) 749
- The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Hussein, Y. M., *et al.* (A) 747
- Macrophage(s),**
- A novel semi-automated technique for measuring inhibition of intracellular mycobacterial growth by macrophage activating factor. Arden Jones, M. P. and Coates, A. R. M. (A) 185
- Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of *M. leprae* viability. Harshan, K. V., *et al.* (O) 316
- Defective macrophage effector function in lepromatous leprosy. Krahenbuhl, J. L., *et al.* (A) 782
- Electron microscopic study of the intracellular fate of *M. leprae* in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. (A) 411
- Functional responses of normal and activated macrophages infected with *M. leprae in vitro*. Sibley, L. D., *et al.* (A) 783
- Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., *et al.* (A) 186
- Importance of determining viability of *M. leprae* inside macrophages—an *in vitro* method using uracil. Vejare, S. and Mahadevan, P. R. (A) 757
- M. leprae*-burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L. (A) 386
- Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* (A) 597
- Macrophages infected *in vitro* with live mycobacteria fail to express Ia antigen after stimulation with lymphokine. Mshana, R. N., *et al.* (A) 407
- Metabolism of *M. leprae* in macrophages. Ramasesh, N., *et al.* (A) 603
- Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro*. Brett, S. J. and Butler, R. (A) 389

The effect of <i>in vivo</i> modulation of macrophage activities on <i>M. lepraemurium</i> infection. Ha, D. K. K., <i>et al.</i> (A)	181
The <i>in vitro</i> microbicidal effects of activated macrophages on <i>M. leprae</i> . Ramasesh, N., <i>et al.</i> (A)	412
Ultracytochemical studies of lysosomal function in the macrophages of human leprosy—I. Bharadwaj, V. P., <i>et al.</i> (O)	328
Malawi,	
Histopathological examination of skin biopsies from an epidemiological study of leprosy in Northern Malawi. McDougall, A. C., <i>et al.</i> (O)	88
Preliminary evaluation of the affect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. (A)	578
Ten years' leprosy control work in Malawi (Central Africa)—I. Methods and outcome after treatment. Boerrigter, G. and Ponnighaus, J. M. (A)	182
Ten years' leprosy control work in Malawi (Central Africa)—II. Patterns of endemicity since 1973. Ponnighaus, J. M. and Boerrigter, G. (A)	183
Malaysia,	
Autopsy findings in 35 cases of leprosy in Malaysia. Jayalakshmi, P., <i>et al.</i> (O)	510
Martinique,	
Primary and secondary dapson resistance of <i>M. leprae</i> in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	672
Metabolism,	
<i>In vitro</i> studies of phenolic glycolipid-I/ ¹⁴ C-palmitate interaction and <i>M. leprae</i> metab- olism. Harris, E. B., <i>et al.</i> (A)	403
[Iodine metabolism in leprosy patients (examination with a method of total body ra- diometry).] Balybin, E. S. (A)	742
Lipase activity in <i>M. leprae</i> —an indicator of metabolic function. Talati, S. and Mo- hadevan, P. R. (A)	389
Metabolic analyses of <i>M. leprae</i> : use in evaluation of <i>in vitro</i> culture media and drug activity. Franzblau, S. G. and Harris, E. B. (A)	402
Metabolism in <i>M. leprae</i> : possible targets for drug interaction. Wheeler, P. R. (A)	589
Metabolism of <i>M. leprae</i> in macrophages. Ramasesh, N., <i>et al.</i> (A)	603
Mexico,	
Asociacion Mexicana de Accion contra la Lepra. (N)	167
Centro Pascua celebrates 50th anniversary. (N)	570
Sensitivity and specificity of the FLA-ABS test for leprosy in Mexican populations. Amezcuca, M. E., <i>et al.</i> (O)	286
Mice,	
Activities of pefloxacin and ciprofloxacin against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	70
Activity of ofloxacin and pefloxacin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)	586
Activity of rifampin in infections of normal mice with <i>M. leprae</i> . Grosset, J. H. and Guelpa-Lauras, C.-C. (S)	847
ADCC function in <i>M. leprae</i> inoculated normal and immunosuppressed mice. Ganguly, N. K., <i>et al.</i> (A)	390
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. (A)	747
Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. (S)	823
Application of the thymectomized-irradiated mouse to the detection of persisting <i>M.</i> <i>leprae</i> . Colston, M. J. (S)	859
Attenuated <i>M. lepraemurium</i> vaccine nonprotective against <i>M. intracellulare</i> infection in mice. Nakanishi, M. (A)	396
Bacillary growth, interleukin-2 production defect, and specific antibody secretion gov- erned by different genetical factors in mice infected subcutaneously with <i>M. leprae</i> - <i>murium</i> . Hoffenbach, A. and Bach, M.-A. (A)	390

Chronic <i>M. avium</i> -complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., <i>et al.</i> (A)	413
Circulating immune complexes in normal and immunosuppressed mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i> (A)	604
Death of <i>M. lepraemurium</i> after multiplication in CBA, BALB/c and nude mice. Resnick, M., <i>et al.</i> (A)	609
Effect of preformed immune complexes on the course of <i>M. leprae</i> infection in normal mice. Kaur, S., <i>et al.</i> (C)	358
Immunization of mice with <i>M. leprae</i> / <i>M. bovis</i> BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. (O)	293
Immunogenic behaviour of <i>M. marinum</i> (SATO) in mice. Srivastava, K. and Singh, N. B. (A)	609
Macrophage chemotaxis in <i>M. leprae</i> infected mice. Kumar, B., <i>et al.</i> (A)	597
Mouse breeding and husbandry. Colston, M. J. and Levy, L. (S)	819
Multiplication of <i>M. leprae</i> in normal mice. Levy, L. (S)	814
[Preliminary observation on the effect of thymic peptide in experimental infection of mice with <i>M. leprae</i> .] Wang, H.-Y. (A)	391
Rifabutin and rifapentine compared with rifampin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)	373
Study of DTH and resistance in <i>M. lepraemurium</i> infection using a T-cell line isolated from mice infected with <i>M. bovis</i> (BCG). Hussein, S., <i>et al.</i> (A)	595
Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with <i>M. lepraemurium</i> . Richard, L., <i>et al.</i> (O)	63
The killing of <i>M. leprae</i> in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. (A)	390
The normal mouse in experimental chemotherapy. Levy, L. (S)	843
Mice, nude,	
Attempts to produce erythema nodosum leprosum in <i>M. leprae</i> -infected nude nu/nu mice with monoclonal antibodies. Chehl, S., <i>et al.</i> (A)	410
Chronic <i>M. avium</i> -complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., <i>et al.</i> (A)	413
Death of <i>M. lepraemurium</i> after multiplication in CBA, BALB/c and nude mice. Resnick, M., <i>et al.</i> (A)	609
Multiplication of <i>M. leprae</i> in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., <i>et al.</i> (S)	889
<i>M. leprae</i> susceptibility of NOD hybrid nude mice. Nakamura, K. and Yogi, Y. (A)	787
The nude mouse—characteristics, breeding and husbandry. McDermott-Lancaster, R. D., <i>et al.</i> (S)	885
Mitsuda, reaction,	
Ability of the phenolic glycolipid-I antigen of <i>M. leprae</i> to elicit a positive Mitsuda response in the armadillo (<i>Dasyus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	299
Prevalence and significance of positive Mitsuda reaction in the nine-banded armadillo (<i>Dasyus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	685
Monkey(s),	
Experimental leprosy in a rhesus monkey: necropsy findings. Baskin, G. B., <i>et al.</i> (O)	109
Lepromin-induced lymphoproliferative response of experimental leprosy monkeys: regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., <i>et al.</i> (A)	751
<i>M. leprae</i> -induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., <i>et al.</i> (A)	417
Naturally acquired leprosy in sooty mangabey monkeys—a second case. Gormus, B. J., <i>et al.</i> (A)	417
Monoclonal antibodies,	
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. (A)	747
Analysis of monoclonal antibodies to <i>M. leprae</i> by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. (A)	594
Attempts to produce erythema nodosum leprosum in <i>M. leprae</i> -infected nude nu/nu mice with monoclonal antibodies. Chehl, S., <i>et al.</i> (A)	410

Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	745
Dominant cell wall proteins of <i>M. leprae</i> recognized by monoclonal antibodies. Britton, W. J., <i>et al.</i> (A)	379
Idiotypic markers of polyclonal B cell activation; public idiotypes shared by monoclonal antibodies derived from patients with systemic lupus erythematosus or leprosy. Mackworth-Young, C., <i>et al.</i> (A)	598
Results of World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., <i>et al.</i> (A)	176
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	743
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	406
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., <i>et al.</i> (A)	176
Multidrug therapy (MDT),	
A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an <i>in vivo</i> and <i>in vitro</i> study. Revankar, C. R., <i>et al.</i> (A)	587
Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., <i>et al.</i> (A)	589
[Effect of multibacillary leprosy patients taking multidrug therapy on the population around them.] Miao, Z. and Ziong, S. (A)	740
Experience with multidrug therapy in paucibacillary leprosy. Bhate, R. D., <i>et al.</i> (A)	172
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., <i>et al.</i> (A)	583
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., <i>et al.</i> (O)	435
[First year's results of multidrug therapy of leprosy.] (China) Wu, Y. (A)	741
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., <i>et al.</i> (A)	584
National conference on MDT of leprosy held in Cheng-du. (China) Ye, G. (N)	363
Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. Becx-Bleumink, M. (A)	578
[Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., <i>et al.</i> (A)	738
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M. (A)	578
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., <i>et al.</i> (A)	576
<i>Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy.</i> (B)	737
Recent developments in the field of multidrug therapy and future research chemotherapy of leprosy. Grosset, J. (A)	581
The use of MDT in the three western regions of Nepal. Kalthoff, P. G. (A)	582
[Treatment of leprosy with two multidrug regimens for one year.] Xu, R., <i>et al.</i> (A)	741
Murine,	
Elastase activity in granulomatous inflammation in experimental murine leprosy. Hsu, P.-S., <i>et al.</i> (A)	381
Experimental murine leprosy and its relevance for the study of resistance to mycobacterial infections in man. Lovik, M. (E)	689
Influence of route of inoculation on anti- <i>M. lepraemurium</i> antibody isotopes in murine leprosy. Hoffenbach, A., <i>et al.</i> (O)	305
Interferon-gamma induces the expression of major histocompatibility complex antigens by <i>in vitro</i> cultured murine Schwann cells. Mshana, R. N., <i>et al.</i> (A)	781
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., <i>et al.</i> (A)	763
Strain-dependent protective effect of adult thymectomy on murine infection by <i>M. lepraemurium</i> . Bach, M.-A. and Hoffenbach, A. (A)	757

Mycobacteria , (see also individual species),	
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with <i>M. leprae</i> . Portaels, F., <i>et al.</i> (A)	180
A novel semi-automated technique for measuring inhibition of intracellular mycobacterial growth by macrophage activating factor. Arden Jones, M. P. and Coates, A. R. M. (A)	185
A recombinant 64 kilodalton protein of <i>M. bovis</i> bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., <i>et al.</i> (A)	594
Analysis of idiotypes expressed by anti-mycobacterial mouse monoclonal antibodies using rabbit antisera. Ivanyi, J. and Praputpittaya, K. (A)	747
Anti-mycobacterial antibodies in saliva. Abe, M., <i>et al.</i> (A)	742
Catalases, peroxidases, and superoxide dismutases in <i>M. leprae</i> and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., <i>et al.</i> (A)	388
Characteristics of human T-cell clones from BCG and killed <i>M. leprae</i> vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., <i>et al.</i> (A)	750
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	745
Cloning and expression of mycobacterial plasmid DNA in <i>Escherichia coli</i> . Labidi, A., <i>et al.</i> (A)	186
Cultivable mycobacteria isolated from 32 newly captured armadillos (<i>Dasypus novemcinctus</i>) from Louisiana. (U.S.A.) Portaels, F., <i>et al.</i> (A)	788
[Cultivation of tubercle and opportunistic mycobacteria on medium with <i>N</i> -alkanes.] Koronelli, T. V. and Fadeeva, N. I. (A)	763
Development of inhibitors of mycobacterial ribonucleotide reductase. Schaper, K.-J., <i>et al.</i> (A)	587
Diagnosis and management of mycobacterial infection and disease in persons with human immunodeficiency virus infection. Centers for Disease Control (A)	608
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., <i>et al.</i> (A)	188
Dissociation between delayed-type hypersensitivity and resistance to pathogenic mycobacteria demonstrated by T-cell clones. Hussein, S., <i>et al.</i> (A)	595
Enzymes and other biochemically active components of mycobacteria. Draper, P. (A)	755
Experimental murine leprosy and its relevance for the study of resistance to mycobacterial infections in man. Lovik, M. (E)	689
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Douvas, G. S., <i>et al.</i> (A)	186
Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A)	764
Immunogenic synthetic peptides against mycobacteria of potential immunodiagnostic and immunoprophylactic value. Patarroyo, M. E., <i>et al.</i> (A)	752
Immunological and biochemical characterization and classification of mycobacterial antigens. Harboe, M. and Wiker, H. G. (A)	746
<i>In vitro</i> activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Ausina, V., <i>et al.</i> (A)	607
<i>In vitro</i> susceptibility of mycobacteria to ciprofloxacin. Collins, C. H. and Uttley, H. C. (A)	185
Influence of environmental mycobacteria on the prevalence of leprosy clinical type. Lyons, N. F. and Naafs, B. (O)	637
Isolation and restriction endonuclease analysis of mycobacterial DNA. Patel, R., <i>et al.</i> (A)	609
Limiting dilution analysis of the human T cell response to mycobacterial antigens from BCG vaccinated individuals and leprosy patients. Brett, S. J., <i>et al.</i> (A)	743
Macrophages infected <i>in vitro</i> with live mycobacteria fail to express Ia antigen after stimulation with live lymphokine. Mshana, R. N., <i>et al.</i> (A)	407
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., <i>et al.</i> (A)	408

Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., <i>et al.</i> (A)	775
Mycobacterial infections in AIDS patients with an emphasis on the <i>M. avium</i> complex. Young, L. S., <i>et al.</i> (A)	765
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to <i>M. avium/M. intracellulare</i> . Franzblau, S. G., <i>et al.</i> (A)	602
Mycobacterial wall lipopolysaccharide: aspects of organization and structure. Draper, P. (A)	781
Peptides as potential immunodiagnostic reagents to detect mycobacterial infections. Shinnick, T. M. (A)	753
Possible role of helper and cytolytic T cells in mycobacterial infections. Kaufmann, S. H. E., <i>et al.</i> (A)	748
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of <i>M. leprae</i> . Kusaka, T. and Mori, T. (A)	387
Resistance to <i>M. lepraemurium</i> is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens <i>in vitro</i> . Brett, S. J. and Butler, R. (A)	389
[Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of lungs.] Karachonsky, M. A., <i>et al.</i> (A)	763
The electron-transparent zone in phagocytized <i>M. avium</i> and other mycobacteria: formation, persistence, and role in bacterial survival. Frehel, C., <i>et al.</i> (A)	762
The influence of killed <i>M. leprae</i> and other mycobacteria on opsonized yeast phagocytosis. Cree, I. A. and Beck, J. S. (A)	381
The measurement of adenylate energy charge (AEC) in mycobacteria, including <i>M. leprae</i> . Lee, Y. N. and Colston, M. J. (A)	180
<i>The Mycobacteria: A Sourcebook</i> (in two parts). Kubica, G. P. and Wayne, L. G., eds. (B)	369
The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., <i>et al.</i> (A)	745
The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., <i>et al.</i> (A)	779
<i>Mycobacterium avium</i>,	
Chronic <i>M. avium</i> -complex infections in athymic (nude) and T-cell depleted (thxb) mice. Collins, F. M., <i>et al.</i> (A)	413
Effect of combined clofazimine and ansamycin therapy on <i>M. avium-M. intracellulare</i> bacteremia in patients with AIDS. Masur, H., <i>et al.</i> (A)	396
Effect of oral exposure of <i>M. avium intracellulare</i> on the protective immunity induced by BCG. Narayanan, S., <i>et al.</i> (A)	608
Mycobacterial infections in AIDS patients with an emphasis on the <i>M. avium</i> complex. Young, L. S., <i>et al.</i> (A)	765
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to <i>M. avium/M. intracellulare</i> . Franzblau, S. G., <i>et al.</i> (A)	602
The electron-transparent zone in phagocytized <i>M. avium</i> and other mycobacteria: formation, persistence, and role in bacterial survival. Frehel, C., <i>et al.</i> (A)	762
Therapeutic implications of inhibition versus killing of <i>M. avium</i> complex by antimicrobial agents. Yajko, D. M., <i>et al.</i> (A)	765
<i>Mycobacterium bovis</i>,	
A recombinant 64 kilodalton protein of <i>M. bovis</i> bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., <i>et al.</i> (A)	594
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of <i>M. leprae</i> , <i>M. tuberculosis</i> , <i>M. vaccae</i> , and <i>M. bovis</i> (BCG). Sinha, S., <i>et al.</i> (O)	42
Immunization of mice with <i>M. leprae/M. bovis</i> BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. (O)	293
MPB59, a widely cross-reacting protein of <i>M. bovis</i> BCG. Wiker, H. G., <i>et al.</i> (A)	610
Study of DTH and resistance in <i>M. lepraemurium</i> infection using a T-cell line isolated from mice infected with <i>M. bovis</i> (BCG). Hussein, S., <i>et al.</i> (A)	595

The characterization and immunoreactivity of a 70 kD protein common to <i>M. leprae</i> and <i>M. bovis</i> (BCG). Britton, W. J., <i>et al.</i> (A)	744
<i>Mycobacterium chelonae</i>,	
Treatment of nonpulmonary infections due to <i>M. fortuitum</i> and <i>M. chelonae</i> on the basis of <i>in vitro</i> susceptibilities. Wallace, R. J., Jr., <i>et al.</i> (A)	188
<i>Mycobacterium fortuitum</i>,	
Restriction endonuclease mapping and cloning of <i>M. fortuitum</i> var. <i>fortuitum</i> plasmid pAL5000. Labidi, A., <i>et al.</i> (A)	187
Treatment of nonpulmonary infections due to <i>M. fortuitum</i> and <i>M. chelonae</i> on the basis of <i>in vitro</i> susceptibilities. Wallace, R. J., Jr., <i>et al.</i> (A)	188
<i>Mycobacterium gordonae</i>,	
Purification of the 65 kD protein from <i>M. gordonae</i> and use in skin test response to <i>M. leprae</i> . Gillis, T. P. and Job, C. K. (O)	54
<i>Mycobacterium intracellulare</i>,	
Attenuated <i>M. lepraemurium</i> vaccine nonprotective against <i>M. intracellulare</i> infection in mice. Nakanishi, M. (A)	396
Effect of combined clofazimine and ansamycin therapy on <i>M. avium</i> - <i>M. intracellulare</i> bacteremia in patients with AIDS. Masur, H., <i>et al.</i> (A)	396
Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to <i>M. avium</i> / <i>M. intracellulare</i> . Franzblau, S. G., <i>et al.</i> (A)	602
<i>Mycobacterium leprae</i>,	
A cooperative taxonomic study of mycobacteria isolated from armadillos infected with <i>M. leprae</i> . Portaels, F., <i>et al.</i> (A)	180
A preliminary report on <i>M. leprae</i> in Aurangabad. (India) Kalyankar, S. D., <i>et al.</i> (A)	605
A rapid silver staining method for identification of <i>M. leprae</i> in histologic sections. Senba, M., <i>et al.</i> (A)	599
Ability of the phenolic glycolipid-I antigen of <i>M. leprae</i> to elicit a positive Mitsuda response in the armadillo (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)	299
Accessory cell function of cells isolated from <i>M. leprae</i> -induced granulomas. Montreewasuwat, N., <i>et al.</i> (A)	383
Activities of pefloxacin and ciprofloxacin against <i>M. leprae</i> in the mouse. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	70
Activity of ofloxacin and pefloxacin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)	586
Activity of rifampin in infections of normal mice with <i>M. leprae</i> . Grosset, J. H. and Guelpa-Lauras, C.-C. (S)	847
Activity of selected beta-lactam antibiotics against <i>M. leprae</i> . Shepard, C. C., <i>et al.</i> . . (O)	322
ADCC function in <i>M. leprae</i> inoculated normal and immunosuppressed mice. Ganguly, N. K., <i>et al.</i> (A)	390
Adherence of <i>M. leprae</i> to Schwann cells <i>in vitro</i> . Itty, B. M., <i>et al.</i> (A)	381
Affinity of <i>M. leprae</i> with Lewis rat schwannoma cell line (Lewis TC 98). Maeda, M. and Narita, M. (A)	598
An HLA-DR3 immune response gene for <i>M. leprae</i> predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. (A)	779
An <i>in vitro</i> system using adenosine triphosphate and ³ H-thymidine to determine drug sensitivity of <i>M. leprae</i> . Dhople, A. M. and Green, K. J. (A)	172
Analysis of monoclonal antibodies to <i>M. leprae</i> by crossed immunoelectrophoresis. Harboe, M. and Ivanyi, J. (A)	594
Antibodies to a synthetic analog of phenolic glycolipid-I of <i>M. leprae</i> in healthy household contacts of patients with leprosy. Menzel, S., <i>et al.</i> (O)	617
Antigens of <i>M. leprae</i> in urine during treatment of patients with lepromatous leprosy. Olcén, P., <i>et al.</i> (A)	384
Antimycobacterial antibodies in <i>Dasypus novemcinctus</i> infected with <i>M. leprae</i> and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., <i>et al.</i> (A)	391
Appearance of a methoxy mycolate-like component by the acid methanolysis of <i>M. leprae</i> . Datta, A. K., <i>et al.</i> (O)	680

Application of the thymectomized-irradiated mouse to the detection of persisting <i>M. leprae</i> . Colston, M. J. (S)	859
Attempts to produce erythema nodosum leprosum in <i>M. leprae</i> -infected nude nu/nu mice with monoclonal antibodies. Chehl, S., <i>et al.</i> (A)	410
Beta-lactamase synthesis in <i>M. leprae</i> . Prabhakaran, K., <i>et al.</i> (A)	587
Biochemical studies on <i>M. leprae</i> . Prabhakaran, K., <i>et al.</i> (A)	389
Can <i>M. leprae</i> enter the body through unbroken epithelium? Job, C. K., <i>et al.</i> (C)	722
Catalases, peroxidases, and superoxide dismutases in <i>M. leprae</i> and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., <i>et al.</i> (A)	388
Characteristics of human T-cell clones from BCG and killed <i>M. leprae</i> vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., <i>et al.</i> (A)	750
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	745
Characterization of the 36 K antigen of <i>M. leprae</i> . Klatser, P. R., <i>et al.</i> (A)	749
Circulating immune complexes in normal and immunosuppressed mice infected with <i>M. leprae</i> . Vaishnavi, C., <i>et al.</i> (A)	604
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of <i>M. leprae</i> viability. Harshan, K. V., <i>et al.</i> (O)	316
Comparative study of immunizing and delayed hypersensitivity eliciting antigens of <i>M. leprae</i> , <i>M. tuberculosis</i> , <i>M. vaccae</i> , and <i>M. bovis</i> (BCG). Sinha, S., <i>et al.</i> (O)	42
Dapsone resistance in <i>M. leprae</i> : a genotypic change. Prabhakaran, K., <i>et al.</i> (A)	181
Dapsone susceptibility of <i>M. leprae</i> before and after 1977. Almeida, J. G. (C)	726
Detection and characterization of antigens of <i>M. leprae</i> reacting with sera from leprosy patients. Sathish, M., <i>et al.</i> (A)	789
Detection of persisting <i>M. leprae</i> by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L. (S)	872
Detection of trehalose monomycolate in <i>M. leprae</i> grown in armadillo tissues. Dhariwal, K. R., <i>et al.</i> (A)	387, 755
Dominant cell wall proteins of <i>M. leprae</i> recognized by monoclonal antibodies. Britton, W. J., <i>et al.</i> (A)	379
Drug susceptibility testing of <i>M. leprae</i> . Ji, B. (S)	830
Effect of 2-mercapto-3-hydrazinoquinoxaline (MHQ) on diphenoloxidase and growth of <i>M. leprae</i> . Prabhakaran, K., <i>et al.</i> (A)	740
Effect of preformed immune complexes on the course of <i>M. leprae</i> infection in normal mice. Kaur, S., <i>et al.</i> (C)	358
Electron microscopic study of the intracellular fate of <i>M. leprae</i> in normal and activated macrophages. Sibley, L. D. and Krahenbuhl, J. L. (A)	411
Events surrounding the recognition of <i>M. leprae</i> in nerves. Ridley, M. J., <i>et al.</i> (O)	99
Exochelin-mediated iron acquisition by the leprosy bacillus <i>M. leprae</i> . Hall, R. M. and Ratledge, C. (A)	387
Expression of major histocompatibility complex class I and class II antigens in human Schwann cell cultures and effects of infection with <i>M. leprae</i> . Samuel, N. M., <i>et al.</i> (A)	753
Expression of recombinant 65 kD protein of <i>M. leprae</i> using the cloning vector pKK223-3. Williams, D. L. and Gillis, T. P. (A)	405
Functional responses of normal and activated macrophages infected with <i>M. leprae</i> <i>in vitro</i> . Sibley, L. D., <i>et al.</i> (A)	783
Further studies of the killing of <i>M. leprae</i> by aminoglycosides: reduced dosage and frequency of administration. Gelber, R. H. (O)	78
[Genetic component of the immune response to <i>M. leprae</i> in healthy individuals.] Bottasso, O. A., <i>et al.</i> (A)	593
[Histochemical study of reverse reactions in <i>M. leprae</i> -infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. (A)	757
HLA class II restricted helper and suppressor clones reactive with <i>M. leprae</i> . de Vries, R. R. P., <i>et al.</i> (A)	745
Host-pathogen interaction—new <i>in vitro</i> drug test systems against <i>M. leprae</i> ; possibilities and limitations. Mahadevan, P. R., <i>et al.</i> (A)	583

- Humoral immune responses to *M. leprae* in human volunteers vaccinated with killed, armadillo-derived *M. leprae*. Gill, H. K., *et al.* (A) 746
- Immunization of mice with *M. leprae*/*M. bovis* BCG admixtures: modulation of the acquired response to BCG. Orme, A. M. (O) 293
- Immunosuppression and cellular immunity reactions in leprosy patients treated with a mixture of *M. leprae* and BCG. Rada, E. M. *et al.* (O) 646
- Importance of determining viability of *M. leprae* inside macrophages—an *in vitro* method using uracil. Vejare, S. and Mahadevan, P. R. (A) 757
- In vitro* proliferation of lymphocytes from human volunteers vaccinated with armadillo-derived, killed *M. leprae*. Gill, H. K., *et al.* (O) 30
- In vitro* studies of phenolic glycolipid-1/¹⁴C-palmitate interaction and *M. leprae* metabolism. Harris, E. B., *et al.* (A) 403
- [Incorporation of ³²P into the phospholipids of *M. leprae*.] David, H. L., *et al.* (A) 185
- Infection of adult trigeminal neurons with *M. leprae in vitro*—a model system. Malaty, R., *et al.* (A) 418
- Infection with other experimental animals with *M. leprae*. Colston, M. J. and Levy, L. (S) 896
- Influence of prior periodic acid oxidation on the acid-fastness of *M. leprae*. Dhople, A. M. (A) 179
- Investigations into cultivation of *M. leprae* in a nasal mucus medium: a preliminary report. Prabhakar, M. C. (C) 561
- Investigations into the cultivation of *M. leprae*; a multifactorial approach. Kato, L. (A) 602
- Isolation of environment-derived *M. leprae* from soil in Bombay. Kazda, J., *et al.* (A) 603
- Limited *in vitro* multiplication of *M. leprae*: application to screening potential antileprosy compounds. Dhople, A. M. and Green, K. J. (A) 601
- Lipase activity in *M. leprae*—an indicator of metabolic function. Talati, S. and Mahadevan, P. R. (A) 389
- M. leprae* antigen-induced suppression of T cell proliferation *in vitro*. Kaplan, G., *et al.* (A) 596
- M. leprae* susceptibility of NOD hybrid nude mice. Nakamura, K. and Yogi, Y. (A) 787
- M. leprae*, probably a microbe-dependent microorganism. Kato, L. (A) 361
- M. leprae*-burdened macrophages are refractory to activation by gamma interferon. Sibley, L. D. and Krahenbuhl, J. L. (A) 386
- M. leprae*-induced lymphoproliferative response of experimental leprosy monkeys; regulatory role of monocyte and lymphocyte subsets. Ohkawa, S., *et al.* (A) 417
- M. leprae*-specific Lyt-2+ T lymphocytes with cytolytic activity. Chiplunkar, S., *et al.* (A) 380
- Macrophage chemotaxis in *M. leprae* infected mice. Kumar, B., *et al.* (A) 597
- Metabolic analyses of *M. leprae*: use in evaluation of *in vitro* culture media and drug activity. Franzblau, S. G. and Harris, E. B. (A) 402
- Metabolism in *M. leprae*: possible targets for drug interaction. Wheeler, P. R. (A) 589
- Metabolism of *M. leprae* in macrophages. Ramasesh, N., *et al.* (A) 603
- Methods for the detection of a specific *M. leprae* antigen in the urine of leprosy patients. Kaldany, R.-R., *et al.* (A) 596
- Microbe dependence on *M. leprae*: a possible intracellular relationship with protozoa. Grange, J. M., *et al.* (C) 565
- Molecular localization and polymorphism of HLA class II restriction determinants defined by *M. leprae*-reactive helper T cell clones from leprosy patients. Ottenhoff, T. H. M., *et al.* (A) 384
- Monitoring of leprosy patients with antibodies to *M. leprae* phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., *et al.* (A) 409
- Multiplication of *M. leprae* in normal mice. Levy, L. (S) 814
- Multiplication of *M. leprae* in the nude mouse, and some applications of nude mice to experimental leprosy. McDermott-Lancaster, R. D., *et al.* (S) 889
- Orientation staining for the demonstration of *M. leprae* in semithin sections. Luder-schmidt, C. (O) 83
- Peptidoglycan and arabinogalactan of *M. leprae*. Draper, P., *et al.* (A) 756
- Phenolic glycolipid-I of *M. leprae* induces altered monocyte oxidative responses *in vitro*. Holzer, T. J., *et al.* (A) 784
- Phenolic glycolipid-I of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* (A) 385

[Preliminary observation on experimental infection with <i>M. leprae</i> in hedgehogs (<i>Eri-naceus europaeus</i> Linne).] Wang, H., <i>et al.</i> (A)	182
[Preliminary observation on the effect of thymic peptide in experimental infection of mice with <i>M. leprae</i> .] Wang, H.-Y. (A)	391
Preliminary study of a <i>M. leprae</i> bacterin vaccine in a human volunteer population in a nonendemic area. Millikan, L. E., <i>et al.</i> (A)	383
[Preliminary study of serologic activity of phenolic glycolipid deacetylate of <i>M. leprae</i> .] Wu, Q., <i>et al.</i> (A)	754
Primary and secondary dapsone resistance of <i>M. leprae</i> in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	672
Purification of the 65 kD protein from <i>M. gordonae</i> and use in skin test response to <i>M. leprae</i> . Gillis, T. P. and Job, C. K. (O)	54
Pyrolysis gas chromatography—mass spectrometry of mycobacterial mycolic acid methyl esters and its application to the identification of <i>M. leprae</i> . Kusaka, T. and Mori, T. (A)	387
Regulatory role of FcR ⁺ and FcR ⁻ monocyte subsets in <i>M. leprae</i> -induced lympho-proliferative response <i>in vitro</i> . Ohkawa, S., <i>et al.</i> (A)	384
Rifabutin and rifapentine compared with rifampin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)	373
Schwann cells and <i>M. leprae</i> . Pandya, S. S. (C)	562
Screening of drugs for activity against <i>M. leprae</i> . Ji, B., <i>et al.</i> (S)	836
Serodiagnosis of leprosy: relationships between antibodies to <i>M. leprae</i> phenolic glycolipid-I and protein antigens. Levis, W. R., <i>et al.</i> (A)	381
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	743
Specific antigen and antibody to <i>M. leprae</i> in the cryoprecipitate of a patient with Lucio phenomenon. Drosos, A. A., <i>et al.</i> (A)	594
[Staining of <i>M. leprae</i> : comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., <i>et al.</i> (A)	387
Structure of <i>M. leprae</i> . Draper, P. (A)	756
Studies of <i>in vitro</i> -cultivated isolates of <i>M. leprae</i> from nodules of lepromatous leprosy patients. Khera, V. R. and Mahadevan, P. R. (A)	405
Suppression of delayed hypersensitivity skin reactions to tuberculin by <i>M. leprae</i> antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., <i>et al.</i> (A)	600
Surveillance for <i>M. leprae</i> infections in a community of nine-banded armadillos. Stall-knecht, D. E., <i>et al.</i> (A)	420
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	406
The allyl group for protection in carbohydrate chemistry. Part 19. The coupling of allyl 2,3-di- <i>O</i> -methyl-4- <i>O</i> -(3,6-di- <i>O</i> -methyl- β -D-glucopyranosyl)- α -L-rhamnopyranoside to bovine serum albumin. Preparation of a diagnostic reagent for antibodies to the major glycolipid of <i>M. leprae</i> (the leprosy bacillus) in human sera. Gigg, J., <i>et al.</i> . . . (A)	745
The carbohydrate-containing antigens of <i>M. leprae</i> . Brennan, P. J. (A)	755
The cell wall of <i>M. leprae</i> ; isolation, composition, and immunogenicity. Brennan, P. J., <i>et al.</i> (A)	782
The characterization and immunoreactivity of a 70 kD protein common to <i>M. leprae</i> and <i>M. bovis</i> (BCG). Britton, W. J., <i>et al.</i> (A)	744
The effect of diet on the growth of <i>M. leprae</i> in mouse foot pads. Foster, R., <i>et al.</i> . . . (A)	403
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with <i>M. leprae</i> . Vadiee, R., <i>et al.</i> (A)	419
The <i>in vitro</i> microbicidal effects of activated macrophages on <i>M. leprae</i> . Ramasesh, N., <i>et al.</i> (A)	412
The influence of killed <i>M. leprae</i> and other mycobacteria on opsonized yeast phago-cytosis. Cree, I. A. and Beck, J. S. (A)	381
The killing of <i>M. leprae</i> in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H. (A)	390
The measurement of adenylate energy charge (AEC) in mycobacteria, including <i>M. leprae</i> . Lee, Y. N. and Colston, M. J. (A)	180

- The use of rodent models in assessing antimicrobial activity against *M. leprae*. Gelber, R. H. (A) 580
- Mycobacterium lepraemurium*,**
 Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection in mice. Nakanishi, M. (A) 396
 Bacillary growth, interleukin-2 production defect, and specific antibody secretion governed by different genetical factors in mice infected subcutaneously with *M. lepraemurium*. Hoffenbach, A. and Bach, M.-A. (A) 390
 Death of *M. lepraemurium* after multiplication in CBA, BALB/c and nude mice. Resnick, M., *et al.* (A) 609
 Influence of route of inoculation on anti-*M. lepraemurium* antibody isotopes in murine leprosy. Hoffenbach, A., *et al.* (O) 305
 [II. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.]
 Ye, S., *et al.* (A) 742
 Resistance to *M. lepraemurium* is correlated with the capacity to generate macrophage activating factor(s) in response to mycobacterial antigens *in vitro*. Brett, S. J. and Butler, R. (A) 389
 Strain-dependent protective effect of adult thymectomy on murine infection by *M. lepraemurium*. Bach, M.-A. and Hoffenbach, A. (A) 757
 Study of DTH and resistance in *M. lepraemurium* infection using a T-cell line isolated from mice infected with *M. bovis* (BCG). Hussein, S., *et al.* (A) 595
 Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium* Richard, L., *et al.* (O) 63
 The effect of *in vivo* modulation of macrophage activities on *M. lepraemurium* infection. Ha, D. K. K., *et al.* (A) 181
- Mycobacterium marinum*,**
 Immunogenic behaviour of *M. marinum* (SATO) in mice. Srivastava, K. and Singh, N. B. (A) 609
- Mycobacterium smegmatis*,**
 Relationship between B-lactamase activity and resistance to B-lactam antibiotics in *M. smegmatis*. Yabu, K., *et al.* (A) 189
- Mycobacterium tuberculosis*,**
 Arthritis induced by a T-lymphocyte clone that responds to *M. tuberculosis* and to cartilage proteoglycans. van Eden, W., *et al.* (A) 188
 Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae*, *M. tuberculosis*, *M. vaccae*, and *M. bovis* (BCG). Sinha, S., *et al.* (O) 42
 Evidence for an HLA-DR4-associated immune-response gene for *M. tuberculosis*. Ottenhoff, T. H. M., *et al.* (A) 609
 Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. (A) 595
 Genetic relatedness among strains of the *M. tuberculosis* complex. Analysis of restriction fragment heterogeneity using cloned DNA probes. Eisenach, K. D., *et al.* (A) 608
 The identification of T cell epitopes in *M. tuberculosis* using human T lymphocyte clones. Lamb, J. R., *et al.* (A) 749
- Mycobacterium vaccae*,**
 Comparative study of immunizing and delayed hypersensitivity eliciting antigens of *M. leprae*, *M. tuberculosis*, *M. vaccae*, and *M. bovis* (BCG). Sinha, S., *et al.* (O) 42
- Nepal,**
 1985–1986 Annual Report—National Leprosy Project. (N) 571
 The use of MDT in the three western regions of Nepal. Kalthoff, P. G. (A) 582
- Nerve(s),**
 An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and Chacko, C. J. G. (O) 515
 Bilateral ulnar nerve abscesses in lepromatous leprosy. Pfaltzgraff, R. E. (C) 553

Correlating Semmes-Weinstein monofilament mappings with sensory nerve conduction parameters in Hansen's disease patients. Breger, D. (A)	414
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., <i>et al.</i> (O)	23
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., <i>et al.</i> (O)	16
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. (A)	176
Events surrounding the recognition of <i>M. leprae</i> in nerves. Ridley, M. J., <i>et al.</i> (O)	99
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., <i>et al.</i> (O)	261
Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. (A)	414
Myelinated and unmyelinated fibers in sural nerve biopsy of a case with lepromatous leprosy—a quantitative approach. Gibbels, E., <i>et al.</i> (O)	333
Nerve tissue culture: a useful model for the study of nerve damage in Hansen's disease. Antia, N. H. and Mukherjee, R. (A)	176
Sciatic nerve in experimental leprosy. Vaishnavi, C., <i>et al.</i> (A)	391
Ulnar nerve abscess in Hansen's disease. Char, G. and Cross, J. N. (A)	375
Netherlands, The,	
Amsterdam will host 1988 International Congress for Tropical Medicine and Malaria. (N)	364
XII International Congress for Tropical Medicine and Malaria. (N)	571
Neuritis,	
Clinical and histopathologic findings in osteoarticular chronic hypertrophic neuritis and differentiation from leprosy. Li, Z., <i>et al.</i> (C)	556
Clinical and histopathological observations in pure neuritic leprosy. Uplekar, M. W. and Antia, N. H. (A)	592
Immunohistochemical studies of leprosy neuritis. Nilsen, R., <i>et al.</i> (A)	751
Primary polyneuritic leprosy in nonhuman primates. Walsh, G. P., <i>et al.</i> (A)	418
[The differentiation of hereditary sensory radicular neuropathy from pure neuritic leprosy.] Zhang, J. and Lu, S. (A)	378
Neuropathy,	
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Sirsat, A. M., <i>et al.</i> (O)	23
Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., <i>et al.</i> (O)	16
Dapsone-induced peripheral neuropathy. Ahrens, E. M., <i>et al.</i> (A)	607
Leprosy neuropathy; cells expressing MHC class II antigens in the lesion. Mshana, R. N. and Nilsen, R. (A)	407
[Thalidomide induced neuropathy.] Chapon, F., <i>et al.</i> (A)	579
[The differentiation of hereditary sensory radicular neuropathy from pure neuritic leprosy.] Zhang, J. and Lu, S. (A)	378
Ulcer border reshaping in the treatment of neuropathic plantar ulcers. Look, J. O. (A)	415
New Caledonia,	
Primary and secondary dapsone resistance of <i>M. leprae</i> in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., <i>et al.</i> (O)	672
Nigeria,	
Leprosy in Cross River State, Nigeria. Brightmer, I. (A)	605
Nose,	
[A study of the histopathologic changes of the nasal mucosa in patients with leprosy.] Kim, H. B. and Kim, M. Y. (A)	596
Investigations into cultivation of <i>M. leprae</i> in a nasal mucus medium: a preliminary report. Prabhakar, M. C. (C)	561
[Reconstruction of the nose after leprosy.] Wintsch, K. (A)	395

Obituaries,		
Ambrosoli, Fr. Dr. Joseph. (Ob)		713
Büngeler, Walter. (Ob)		714
Ofloxacin,		
Activity of ofloxacin and pefloxacin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)		586
Effect of ofloxacin on experimental leprosy. Ito, T., <i>et al.</i> (A)		778
Pakistan,		
Leprosy in Pakistan. Pfau, R. and Haq, G. (A)		370
Paraguay,		
Report of the joint leprosy-tuberculosis project in Paraguay. Alvarenga, A. E. (A)		576
[The Paraguay project; a short report on a leprosy/tuberculosis eradication program.]		
Freerksen, E. (A)		182
Pathology,		
Dapsone neuropathy—report of three cases and pathologic features of a motor nerve.		
Sirsat, A. M., <i>et al.</i> (O)		23
Leprosy: cause, transmission and a new theory of pathogenesis. Reich, C. V. (A)		738
Ocular leprosy: a case report and discussion of the pathology. House, P. H. (A)		174
[Pathomorphology of leprosy.] Warzok, V. R., <i>et al.</i> (A)		576
The pathology of leprosy as a reflection of the host parasite relationship. Ridley, D. S.		
..... (A)		752
Pefloxacin,		
Activities of pefloxacin and ciprofloxacin against <i>M. leprae</i> in the mouse. Guelpa-Lauras,		
C.-C., <i>et al.</i> (O)		70
Activity of ofloxacin and pefloxacin against <i>M. leprae</i> in mice. Pattyn, S. R. (A)		586
Peroxidase,		
Catalases, peroxidases, and superoxide dismutases in <i>M. leprae</i> and other mycobacteria		
studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis.		
Lygren, S. T., <i>et al.</i> (A)		388
Phagocytes,		
The electron-transparent zone in phagocytized <i>M. avium</i> and other mycobacteria: for-		
mation, persistence, and role in bacterial survival. Frehel, C., <i>et al.</i> (A)		762
The influence of killed <i>M. leprae</i> and other mycobacteria on opsonized yeast phago-		
cytosis. Cree, I. A. and Beck, J. S. (A)		381
Pharmacokinetics,		
Clinical pharmacokinetics of dapsone. Zuidema, J., <i>et al.</i> (A)		374
Effect of clofazimine and dapsone on rifampicin (Lositil) pharmacokinetics in multi-		
bacillary and paucibacillary leprosy cases. Mehta, J., <i>et al.</i> (A)		584
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krish-		
na, D. R., <i>et al.</i> (A)		372
Pharmacokinetics in drug screening. Grosset, J. H. (S)		852
Pharmacokinetics of clofazimine in healthy volunteers. Schaad-Lanyi, Z., <i>et al.</i> (O)		9
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy.		
Venkatesan, K., <i>et al.</i> (A)		373
Phenolic glycolipid,		
A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I		
in sera from leprosy patients. Kumar, S., <i>et al.</i> (A)		178
Ability of the phenolic glycolipid-I antigen of <i>M. leprae</i> to elicit a positive Mitsuda		
response in the armadillo (<i>Dasypus novemcinctus</i>). Job, C. K., <i>et al.</i> (O)		299
Antibodies to a synthetic analog of phenolic glycolipid-I of <i>M. leprae</i> in healthy house-		
hold contacts of patients with leprosy. Menzel, S., <i>et al.</i> (O)		617
Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in		
individual patients. Miller, R. A., <i>et al.</i> (O)		633
Cellular and humoral immune response to a phenolic glycolipid antigen (PGL-I) in		
patients with leprosy. Koster, F. T., <i>et al.</i> (A)		597

<i>In vitro</i> studies of phenolic glycolipid- ¹⁴ C-palmitate interaction and <i>M. leprae</i> metabolism. Harris, E. B., <i>et al.</i> (A)	403
Monitoring of leprosy patients with antibodies to <i>M. leprae</i> phenolic glycolipid-I and a synthetic glycoconjugate. Meeker, H. C., <i>et al.</i> (A)	409
Phenolic glycolipid-I of <i>M. leprae</i> induces altered monocyte oxidative responses <i>in vitro</i> . Holzer, T. J., <i>et al.</i> (A)	784
Phenolic glycolipid-I of <i>M. leprae</i> induces general suppression of <i>in vitro</i> concanavalin A responses unrelated to leprosy type. Prasad, H. K., <i>et al.</i> (A)	385
[Preliminary study of serologic activity of phenolic glycolipid deacetylate of <i>M. leprae</i> .] Wu, Q., <i>et al.</i> (A)	754
Serodiagnosis of leprosy: relationships between antibodies to <i>M. leprae</i> phenolic glycolipid-I and protein antigens. Levis, W. R., <i>et al.</i> (A)	381
Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., <i>et al.</i> (A)	743
The evolution of IgG and IgM antibodies to phenolic glycolipid-I in armadillos inoculated with <i>M. leprae</i> . Vadiee, R., <i>et al.</i> (A)	419
Philippines, The,	
Leonard Wood Memorial (LWM) seeking Director of Scientific Facility. (N)	571
LWM course offered at Cebu. (N)	365
Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, The Philippines. Douglas, J. T., <i>et al.</i> (C)	718
Phospholipids,	
[Incorporation of ³² P into the phospholipids of <i>M. leprae</i> .] David, H. L., <i>et al.</i> (A)	185
Phytohemagglutinin,	
Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. (A)	385
Polynesia,	
Seroepidemiological study on 724 household contacts of leprosy patients in French Polynesia using disaccharide-octyl-BSA as antigen. Chanteau, S., <i>et al.</i> (O)	626
Social and demographic aspects of a leprosy epidemic on a Polynesian atoll: implications of pattern. Lieber, M. D. and Lieber, E. B. (O)	468
Pregnancy,	
Leprosy in pregnancy. Duncan, M. E. (A)	174
Protein(s),	
A recombinant 64 kilodalton protein of <i>M. bovis</i> bacillus Calmette-Guérin specifically stimulates human T4 clones reactive to mycobacterial antigens. Emmrich, F., <i>et al.</i> (A)	594
Characterization of antibody-reactive epitopes on the 65-kilodalton protein of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	594
Characterization of mycobacterial species specificity of 14 separate epitopes which reacted with monoclonal antibodies to the 65,000 molecular weight protein molecule of <i>M. leprae</i> . Buchanan, T. M., <i>et al.</i> (A)	745
Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., <i>et al.</i> (O)	277
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. Wallis, R. S., <i>et al.</i> (A)	188
Dominant cell wall proteins of <i>M. leprae</i> recognized by monoclonal antibodies. Britton, W. J., <i>et al.</i> (A)	379
Efficient mapping of protein antigenic determinants. Mehra, V., <i>et al.</i> (A)	382
Expression of recombinant 65 kD protein of <i>M. leprae</i> using the cloning vector pKK223-3. Williams, D. L. and Gillis, T. P. (A)	405
Genes for the major protein antigens of <i>M. tuberculosis</i> : the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. (A)	595
Monitoring of leprosy patients for antibodies to mycobacterial protein, glycolipid and lipopolysaccharide antigens. Levis, W. R., <i>et al.</i> (A)	408
MPB59, a widely cross-reacting protein of <i>M. bovis</i> BCG. Wiker, H. G., <i>et al.</i> (A)	610

Purification of the 65 kD protein from <i>M. goodsonae</i> and use in skin test response to <i>M. leprae</i> . Gillis, T. P. and Job, C. K. (O)	54
S-100 Protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. Fleury, R. N. and Bacchi, C. E. (O)	338
Serodiagnosis of leprosy: relationships between antibodies to <i>M. leprae</i> phenolic glycolipid-I and protein antigens. Levis, W. R., <i>et al.</i> (A)	381
Significant enhanced superoxide anion (O ₂ ⁻) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., <i>et al.</i> (A)	746
Solid phase peptide synthesis of epitopes that react with monoclonal antibodies to the 65,000 dalton protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	743
Studies on serum proteins in leprosy by polyacrylamide gel electrophoresis (PAGE). Patil, S. A., <i>et al.</i> (A)	175
Synthesis of epitopes of monoclonal antibodies to the 65 kD protein of <i>M. leprae</i> . Anderson, D. C., <i>et al.</i> (A)	406
The characterization and immunoreactivity of a 70 kD protein common to <i>M. leprae</i> and <i>M. bovis</i> (BCG). Britton, W. J., <i>et al.</i> (A)	744
Prothionamide,	
Effect of prothionamide on the infectivity of lepromatous leprosy. Girdhar, A., <i>et al.</i> ... (A)	739
Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Jenner, P. J. and Smith, S. E. (A)	581
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C. (A)	374
Psychosocial,	
[On the mental care of leprosy patients.] Tan, D. and Zhang, Z. (A)	761
[Psychosis of leprosy patients from social discrimination and somatic deformities.] Pan, X., <i>et al.</i> (A)	760
Psychosocial dimensions of drug default in leprosy. Anandaraj, H. (A)	375
Radioimmunoassay,	
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., <i>et al.</i> (A)	176
Rat(s),	
Affinity of <i>M. leprae</i> with Lewis rat schwannoma cell line (Lewis TC 98). Maeda, M. and Narita, M. (A)	598
Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., <i>et al.</i> (A)	776
Detection of persisting <i>M. leprae</i> by inoculation of the neonatally thymectomized rat. Gelber, R. H. and Levy, L. (S)	872
The neonatally thymectomized rat as a model of the lepromatous patient. Gelber, R. H. (S)	879
Reaction, leprosy,	
An unusual bullous reaction in borderline leprosy. Singh, K. (A)	592
Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (O)	36
Etiological factors in delayed-type hypersensitivity reactions in leprosy. Klenerman, P. (E)	702
[Histochemical study of reverse reactions in <i>M. leprae</i> -infected armadillos.] Juscenko, A. A. and Vishnevetsky, F. E. (A)	757
HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., <i>et al.</i> (O)	261
Immunoprofile of reactions in leprosy. Sehgal, V. N., <i>et al.</i> (A)	386
Reversal reaction—management with topical corticosteroids. Srinivas, C. R., <i>et al.</i> (C)	355
T _γ , T _μ and B lymphocytes in erythema nodosum leprosum reactions of leprosy. Rao, T. D. and Rao, P. R. (A)	599
The "Ellis" and "Ryrie" tests. Naafs, B., <i>et al.</i> (A)	591
The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Sehgal, V. N., <i>et al.</i> (A)	179

Type 1 reactions in leprosy—heterogeneity in T-cell functions related to the background leprosy type. Laal, S., <i>et al.</i>	(O)	481
Rehabilitation,		
[A survey of persons living in leproseries after leprosy cured.] Shu, H., <i>et al.</i>	(A)	768
Rehabilitation surgery for leprosy handicapped at a rural leprosy colony. Shah, A. and Bhagat, N.	(A)	607
Simplified surgical technique for flexible clawed hand rehabilitation. Chevillard, A. J.	(C)	160
Relapse(s),		
[Inadequate treatment in multibacillary leprosy and incubation times for relapses.] Pattyn, S. R., <i>et al.</i>	(A)	586
Multiple relapses in borderline leprosy—a case report. Ramachandran, A. and Seshadri, P. S.	(A)	591
[Relapse of leprosy among 599 arrested cases in the city of Baoji.] (China) Deng, Y., <i>et al.</i>	(A)	739
[Relapse of leprosy in Jinju hospital for old-disabled persons.] (China) Liu, W.	(A)	740
Rifampin,		
Activity of rifampin in infections of normal mice with <i>M. leprae</i> . Grosset, J. H. and Guelpa-Lauras, C.-C.	(S)	847
Comparison of three regimens containing rifampin for treatment of paucibacillary leprosy patients. Katoch, K., <i>et al.</i>	(O)	1
Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Mehta, J., <i>et al.</i>	(A)	584
[Efficacy of combined treatments involving 6 months' administration of rifampin in multibacillary leprosy.] Pattyn, S. R., <i>et al.</i>	(A)	740
Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., <i>et al.</i>	(A)	604
Pharmacokinetic interaction between dapsone and rifampicin in leprosy patients. Krishna, D. R., <i>et al.</i>	(A)	372
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., <i>et al.</i>	(A)	763
Rifabutin and rifapentine compared with rifampin against <i>M. leprae</i> in mice. Pattyn, S. R.	(A)	373
[Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of the lungs.] Karachunsky, M. A., <i>et al.</i>	(A)	763
Rifampicin for nontuberculous infections? Gruneberg, R. N., <i>et al.</i>	(A)	186
[Seven years' follow-up of multibacillary patients treated with RFP or B663 for a short time.] Li, W. and Zhang, Y., <i>et al.</i>	(A)	372
[Sixty-eight cases of multibacillary leprosy treated with RFP or RFP plus DDS.] Zhou, S. and Zhu, S.	(A)	374
T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., <i>et al.</i>	(A)	610
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy. Venkatesan, K., <i>et al.</i>	(A)	373
The killing of <i>M. leprae</i> in mice by various dietary concentrations of dapsone and rifampin. Gelber, R. H.	(A)	390
The Malta experience: isoprodian-rifampicin combination treatment for leprosy. Depasquale, G.	(A)	579
[Therapeutic effects of rifampicin, clofazimine and dapsone in multibacillary leprosy in the fieldwork—results of a year's treatment.] Li, W., <i>et al.</i>	(A)	372
[Treatment of 24 cases of multibacillary leprosy with DDS, RFP, and PTH.] Zheng, C.	(A)	374
Update on rifampin drug interactions. Baciewicz, A. M., <i>et al.</i>	(A)	577
Saliva,		
Anti-mycobacterial antibodies in saliva. Abe, M., <i>et al.</i>	(A)	742
Sarcoidosis,		
[Behavior of the intradermal reaction with lepromin in patients with sarcoidosis.] Gu-maraes Proenca, N., <i>et al.</i>	(A)	177

Screening,

- Limited *in vitro* multiplication of *M. leprae*: application to screening potential antileprosy compounds. Dhople, A. M. and Green, K. J. (A) 601
- III. *M. lepraemurium* in cell culture, possibly useful for screening antileprosy drugs.] Ye, S., *et al.* (A) 742
- Mass screening in leprosy endemic areas of Turkey; preliminary report. Saylan, T. and Aytakin, A. H. (A) 183
- Mycobacterial plasmids: screening and possible relationship in antibiotic resistance to *M. avium/M. intracellulare*. Franzblau, S. G., *et al.* (A) 602
- Pharmacokinetics in drug screening. Grosset, J. H. (S) 852
- Screening of drugs for activity against *M. leprae*. Ji, B., *et al.* (S) 836

Senegal,

- [Clinical and bacteriological evaluation 8 years after triple drug chemotherapy for multibacillary leprosy in Senegal.] Dousset-Faure, I., *et al.* (A) 739
- [Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* (A) 584
- [Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., *et al.* (A) 738
- Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* (O) 672

Sensation(s),

- An attempt to reduce the loss of pain and touch sensations in leprosy patients. Jain, G. L., *et al.* (A) 175

Sensitivity, drug,

- An *in vitro* system using adenosine triphosphate and ³H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. (A) 172

Serodiagnosis,

- Gelatin-particle agglutination test for serodiagnosis of leprosy—a new simple test useful for large-scale field study. Izumi, S., *et al.* (A) 790
- Serodiagnosis of leprosy: relationships between antibodies to *M. leprae* phenolic glycolipid-I and protein antigens. Levis, W. R., *et al.* (A) 381
- Simplification and standardization of serodiagnostic tests for leprosy of phenolic glycolipid-I (PGL-I) antigen. Aguado Sanchez, G., *et al.* (A) 743
- Some strategies for developing serodiagnosis of leprosy. Abe, M. (A) 774

Serum,

- A dot enzyme immunoassay for detection of IgM antibodies against phenolic glycolipid-I in sera from leprosy patients. Kumar, S., *et al.* (A) 178
- Antimycobacterial antibodies in *Dasyatis novemcinctus* infected with *M. leprae* and their correlation with the serum levels of lactate dehydrogenase. Rojas-Espinosa, O., *et al.* (A) 391
- Binding of dapsone and its analogues to human serum albumin. Karp, W. B., *et al.* (A) 172
- Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Kerr, M. A., *et al.* (A) 748
- Clinical significance of changes in serum proteins, immunoglobulins, and autoantibodies in leprosy. Rawlinson, W. D., *et al.* (O) 277
- Detection and characterization of antigens of *M. leprae* reacting with sera from leprosy patients. Sathish, M., *et al.* (A) 789
- [Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., *et al.* (A) 378
- Serial estimation of serum lactic dehydrogenase & its isoenzymes in an active pulmonary tuberculosis. Zawar, P. B., *et al.* (A) 766
- Soluble serum interleukin 2 receptor levels in leprosy patients. Tung, K. S. K., *et al.* (A) 753
- Studies on serum proteins in leprosy by polyacrylamide gel electrophoresis (PAGE). Patil, S. A., *et al.* (A) 175
- The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes. Hussein, Y. M., *et al.* (A) 747

The repertoire of mycobacterial antigens recognized by peripheral blood cells and sera of healthy leprosy patient contacts. Converse, P. J., <i>et al.</i> (A)	779
Undernutrition in lepromatous leprosy, Part II. Altered levels of serum elements; their association with the disease and not with food deprivation. Rao, K. N. and Saha, K. (A)	377
Skin,	
Acid-fast bacilli detected in umbilical cord and skin specimens. Mori, T. (A)	786
Distribution and turnover of Langerhans cells during delayed immune responses in human skin. Kaplan, G., <i>et al.</i> (A)	748
<i>In situ</i> identification of activated Ta1+ T lymphocytes in human leprosy skin lesions. Shen, J.-Y., <i>et al.</i> (O)	494
Suppression of delayed hypersensitivity skin reactions to tuberculin by <i>M. leprae</i> antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., <i>et al.</i> (A)	600
Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	179
T-lymphocyte clones from leprosy skin lesions. Modlin, R. L., <i>et al.</i> (A)	750
[The foamy cells in skin lesions of arrested lepromatous patients.] Zhu, W., <i>et al.</i> (A)	754
The role of IFN-gamma in the regulation of DTH in human skin. Kaplan, G. and Cohn, Z. A. (A)	785
[Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu, J., <i>et al.</i> (A)	382
Skin smear(s),	
Retrospective analysis of smear examinations from multiple sites in multibacillary leprosy. Bhatia, V. N., <i>et al.</i> (A)	173
WHO guidelines for skin smears. (—)	421
Skin test(s),	
Immunohistologic comparison between armadillo-derived leprosin and standard lepromin skin tests in leprosy patients. Narayanan, R. B., <i>et al.</i> (A)	598
Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. . . . (A)	385
Purification of the 65 kD protein from <i>M. gordonae</i> and use in skin test response to <i>M. leprae</i> . Gillis, T. P. and Job, C. K. (O)	54
Spain,	
XI Ibero-Latin American Congress of Dermatology Leprosy Symposium. Gatti, J. C. . . . (N)	731
Fontilles International Courses 1987. (N)	365
Sperm,	
Antispermatozoal antibodies in leprosy with special reference to their morphological patterns. Gupta, S. C., <i>et al.</i> (A)	174
Stain(s),	
A cold staining method for acid-fast bacilli. Vasanthakumari, R., <i>et al.</i> (A)	389
A rapid silver staining method for identification of <i>M. leprae</i> in histologic sections. Senba, M., <i>et al.</i> (A)	599
Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J. (A)	600
[Comparative investigation on two modified techniques of acid-fast stain.] Xie, Y. and Dong, X. (A)	754
Comparison of radiometric macrophage assay and fluorescein diacetate/ethidium bromide staining for evaluation of <i>M. leprae</i> viability. Harshan, K. V., <i>et al.</i> (O)	316
Orientation staining for the demonstration of <i>M. leprae</i> in semithin sections. Luder-schmidt, C. (O)	83
[Staining of <i>M. leprae</i> : comparison between Lepyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., <i>et al.</i> . . . (A)	387
Subclinical,	
The detection of subclinical leprosy using a monoclonal based radioimmunoassay. Ashworth, M., <i>et al.</i> (A)	176
Sulfone,	
Method for detecting sulfones in urine. Jaled, M. M., <i>et al.</i> (C)	560

Superoxide,

- Catalases, peroxidases, and superoxide dismutases in *M. leprae* and other mycobacteria studied by crossed immunoelectrophoresis and polyacrylamide gel electrophoresis. Lygren, S. T., *et al.* (A) 388
- Significant enhanced superoxide anion (O₂⁻) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* (A) 746

Suppression,

- BCG-induced suppressor T cells optimal conditions for *in vitro* induction and mode of action. Mustafa, A. S. and Godal, T. (A) 187
- Cimetidine inhibits suppressor factor production in Ethiopian lepromatous leprosy patients. Converse, P. J., *et al.* (C) 548
- HLA class II immune response and suppression genes in leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. (R) 521
- HLA class II restricted helper and suppressor clones reactive with *M. leprae*. de Vries, R. R. P., *et al.* (A) 745
- Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E. E., *et al.* (A) 384
- M. leprae* antigen-induced suppression of T cell proliferation *in vitro*. Kaplan, G., *et al.* (A) 596
- Phenolic glycolipid-I of *M. leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. Prasad, H. K., *et al.* (A) 385
- Significant enhanced superoxide anion (O₂⁻) monocytes of lepromatous leprosy patients stimulated with liposome and suppression by C-reactive protein (CRP). Hokama, Y., *et al.* (A) 746
- Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* (A) 600
- Suppressor response in lepromatous leprosy patients: role of Leu2a cells. Sasiain, M. del C., *et al.* (A) 385
- Suppressor T cells for delayed-type hypersensitivity in susceptible mice infected with *M. lepraemurium*. Richard, L., *et al.* (O) 63
- Suppressor T lymphocytes from lepromatous leprosy skin lesions. Modlin, R. L., *et al.* (A) 179

Surgery,

- Biomechanics of tendon transfers. Brand, P. W. (A) 607
- [Realistic organization of surgery in countries with endemic leprosy.] Bourrel, P. (A) 184
- [Reconstruction of the nose after leprosy.] Wintsch, K. (A) 395
- Rehabilitation surgery for leprosy handicapped at a rural leprosy colony. Shah, A. and Bhagat, N. (A) 607
- Simplified surgical technique for flexible clawed hand rehabilitation. Chevillard, A. J. (C) 160
- Surgical correction of intrinsic minus fingers. Palande, D. D. (A) 606
- Surgical correction of thumb with ulnar or ulnar median paralysis. Palande, D. D. (A) 606
- Surgical treatment of plantar ulcers in leprosy. Rao, P. T. and Jena, S. K. (A) 395

Switzerland,

- Leprosy sample surveys. (N) 168
- Training in Leprosy; WHO publication. (N) 168

Tahiti,

- Primary and secondary dapsone resistance of *M. leprae* in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Guelpa-Lauras, C.-C., *et al.* (O) 672

Testing,

- Drug susceptibility testing of *M. leprae*. Ji, B. (S) 830
- Immunodiagnostic tests for leprosy; a need for standards. Ramanathan, V. D. (C) 721
- Mycobacterial carbohydrate antigens for serologic testing of leprosy. Levis, W. R., *et al.* (A) 775
- The "Ellis" and "Ryrie" tests. Naafs, B., *et al.* (A) 591
- The repeatability of testing with Semmes-Weinstein monofilaments. Beli-Krotoski, J. and Tomancik, E. (A) 394

[Testing of the hypothesis of multifactorial type inheritance of predisposition to pulmonary tuberculosis.] Berezousky, B. A., <i>et al.</i> (A)	761
Tetanus,	
Tetanus in a case of lepromatous leprosy. Parikh, A. A. and Shah, B. H. (A)	591
Thalidomide,	
[Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemagglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study.] Arruda, W. O., <i>et al.</i> (A)	378
Thalidomide in leprosy—study of 94 cases. Parikh, D. A., <i>et al.</i> (A)	585
[Thalidomide induced neuropathy.] Chapon, F., <i>et al.</i> (A)	579
The Leprosy Mission (TLM),	
Dr. Thangaraj and Mr. Askew retire. (N)	730
The Leprosy Mission (TLM) International 1987 changes. (N)	169
THELEP,	
Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical, etc. (A)	588
[Staining of <i>M. leprae</i> : comparison between Lepeyssonie and Causse's technique and THELEP's technique to evaluate the bacteriological index.] Baquillon, G., <i>et al.</i> (A)	387
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., <i>et al.</i> (S)	807
The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. (S)	864
Therapy, (see also Chemotherapy),	
A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an <i>in vivo</i> and <i>in vitro</i> study. Revankar, C. R., <i>et al.</i> (A)	587
Antibiotic therapy for leprosy. Jacobson, R. R. (A)	372
Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients. Miller, R. A., <i>et al.</i> (O)	633
Clinical problems in the initiation and assessment of multidrug therapy. Waters, M. F. R., <i>et al.</i> (A)	589
Effect of combined clofazimine and ansamycin therapy on <i>M. avium-M. intracellulare</i> bacteremia in patients with AIDS. Masur, H., <i>et al.</i> (A)	396
[Effect of multibacillary leprosy patients taking multidrug therapy on the population around them.] Miao, Z. and Ziong, S. (A)	740
Evaluation of nerve function deficit, its improvement by nerve decompression or corticosteroid therapy. Shah, A. (A)	176
Experience with multidrug therapy in paucibacillary leprosy. Bhate, R. D., <i>et al.</i> (A)	172
Factors influencing clinic attendance during the multidrug therapy of leprosy. Langhorne, P., <i>et al.</i> (A)	583
Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population—Curupaiti State Hospital, Rio de Janeiro, Brazil. Andrade, V. L. G., <i>et al.</i> (O)	435
[First year's results of multidrug therapy of leprosy.] Wu, Y. (A)	741
Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy. Balakrishnan, S., <i>et al.</i> (A)	577
Methemoglobinemia from dapsone therapy for a suspected brown spider bite. Iserson, K. V. (A)	581
Monitoring of patient neural status during drug therapy—preliminary study. Bell-Krotoski, J. (A)	414
[Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., <i>et al.</i> (A)	584
Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. Beex-Bleumink, M. (A)	578
[Practical problems of multidrug therapy management in Senegal.] Naudin, J. C., <i>et al.</i> (A)	738
[Problems in applying the practice of multidrug therapy in leprosy in West Africa.] Nebout, M., <i>et al.</i> (A)	576
<i>Questions and Answers on the Implementation of Multiple Drug Therapy (MDT) for Leprosy.</i> (B)	737

- Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy. Grosset, J. (A) 581
- Single bacterial cell mass analysis: a rapid test method in leprosy therapy control. Seydel, U. and Lindner, B. (A) 603
- Thymidine,**
- An *in vitro* system using adenosine triphosphate and ³H-thymidine to determine drug sensitivity of *M. leprae*. Dhople, A. M. and Green, K. J. (A) 172
- Thymidine uptake as an indicator of cell ability and *in vitro* growth of *M. leprae*. Dhople, A. M. (A) 402
- Tissue(s),**
- Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients. Cocito, C. and Delville, J. (A) 600
- Detection of trehalose monomycolate in *M. leprae* grown in armadillo tissues. Dhariwal, K. R., *et al.* (A) 387, 755
- Lipid composition of human leprosy tissue. Kumar, B., *et al.* (C) 162
- Nerve tissue culture: a useful model for the study of nerve damage in Hansen's disease. Antia, N. H. and Mukherjee, R. (A) 176
- Training,**
- ILEP Catalogue on Training, 1987. (N) 734
- Teaching of Leprosy. Proceedings of a Symposium Held on the Occasion of the 20th Annual General Meeting of the All Africa Leprosy and Rehabilitation Training Centre (ALERT)*. Harboe, M., ed. (B) 574
- Training in Leprosy*; WHO publication. (N) 168
- Trial(s),**
- Application of the mouse foot-pad technique in immunologically normal mice in support of clinical drug trials, and a review of earlier clinical drug trials in lepromatous leprosy. Levy, L. (S) 823
- Characteristics of patients in the THELEP trials of chemotherapy of leprosy at Bamako and Chingleput. Subcommittee on Clinical, etc. (A) 588
- Chemotherapy trials in the neonatally thymectomized Lewis rat: a model for the study of the therapy of lepromatous leprosy. Gelber, R. H., *et al.* (A) 776
- Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. (A) 762
- [Multidrug therapy trial for leprosy in Senegal: first results about hepatic tolerance of multibacillary patients—therapeutic proposals.] Millan, J., *et al.* (A) 584
- The THELEP controlled clinical drug trials. Subcommittee on Clinical, etc. (S) 864
- Tuberculin,**
- Lack of tuberculin activity of synthetic peptides. Toida, I., *et al.* (A) 188
- [Study of new method for the application of tuberculin ointment for cutaneous use in comparison with the Mantoux test.] Levi, D. T., *et al.* (A) 763
- Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* (A) 600
- Tuberculoid leprosy,**
- An HLA-DR3 immune response gene for *M. leprae* predisposes to tuberculoid leprosy. Ottenhoff, T. H. M. and de Vries, R. R. P. (A) 779
- Cold reactive lymphocytotoxic antibodies in patients with tuberculoid and lepromatous leprosy. Naik, S., *et al.* (O) 273
- Dapsone-induced neuropathy compounds Hansen's disease nerve damage: an electrophysiological study in tuberculoid patients. Sebille, A., *et al.* (O) 16
- HLA antigens and neural reversal reactions in Ethiopian borderline tuberculoid leprosy patients. Ottenhoff, T. H. M., *et al.* (O) 261
- Photoactivated 8-methoxypsoralen in repigmentation of tuberculoid leprosy. Srinivas, C. R., *et al.* (C) 159
- Suppression of delayed hypersensitivity skin reactions to tuberculin by *M. leprae* antigens in patients with lepromatous and tuberculoid leprosy. Sengupta, U., *et al.* (A) 600

Tuberculosis,

- [Asymmetry of dermatoglyphical indices and topics of tuberculosis process in the lungs.] Zosimov, A. N. and Khodzitskaya, V. K. (A) 766
- Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated subjects and tuberculosis patients; recognition of recombinant mycobacterial antigens. Mustafa, A. S., *et al.* (A) 750
- [Chlorprothixen efficacy in combined treatment of patients with pulmonary tuberculosis.] Gunich, L. A., *et al.* (A) 762
- Evaluation of subdermal biodegradable implants incorporating rifampicin as a method of drug delivery in experimental tuberculosis of guinea pigs. Mathur, I. S., *et al.* (A) 604
- Genes for the major protein antigens of *M. tuberculosis*: the etiologic agents of tuberculosis and leprosy share an immunodominant antigen. Husson, R. N. and Young, R. C. (A) 595
- Histochemical demonstration of mycobacterial antigen, specific antibody and complement in the lesions of tuberculosis. Ridley, M. J. and Ridley, D. S. (A) 764
- Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Fox, W. and Kee, T. S. (A) 762
- Management of non-respiratory tuberculosis. Wilkins, E. G. L. and Roberts, C. (A) 765
- Phytohemagglutinin as a skin test for the evaluation of immune competence in patients with leprosy and tuberculosis and in controls. Samuel, N. M. and Stanford, J. L. (A) 385
- Rationale for the histological spectrum of tuberculosis; a basis for classification. Ridley, D. S. and Ridley, M. J. (A) 764
- Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Khor, M., *et al.* (A) 763
- [Regulatory subpopulations of T lymphocytes in patients with pulmonary tuberculosis.] Averbakh, M. M., *et al.* (A) 761
- Report of the joint leprosy-tuberculosis project in Paraguay. Alvarenga, A. E. (A) 576
- [Rifampicin effect on L-transformation of mycobacterial population in patients with destructive tuberculosis of the lungs.] Karachunsky, M. A., *et al.* (A) 763
- [Rosette-forming T lymphocytes of different types in patients with pulmonary tuberculosis.] Petrashenko, A. I. (A) 764
- Serial estimation of serum lactic dehydrogenase & its isoenzymes in an active pulmonary tuberculosis. Zawar, P. B., *et al.* (A) 766
- [Significance of certain biochemical and immunological indices in estimation of activity of limited tuberculosis of the lungs.] Kostina, Z. I., *et al.* (A) 763
- [Studies on the tuberculosis infection in a cattle breeding area in sahelian Africa.] Rey, J. L., *et al.* (A) 396
- T-cell subpopulations in tuberculosis and the effects of rifampicin. Vidhidharm, A., *et al.* (A) 610
- [Testing of the hypothesis of multifactorial type inheritance of predisposition to pulmonary tuberculosis.] Berezousky, B. A., *et al.* (A) 761
- [The Paraguay project; a short report on a leprosy/tuberculosis eradication program.] Freerksen, E. (A) 182
- The relationship between natural killer cell activity and delayed-type hypersensitivity reaction of 2,4-dinitrochlorobenzene in the spectrum of chronic, intractable pulmonary tuberculosis. Yoneda, T., *et al.* (A) 610

Turkey,

- Mass screening in leprosy endemic areas of Turkey; preliminary report. Saylan, T. and Aytakin, A. H. (A) 183

U.K.,

- Dr. Thangaraj and Mr. Askew retire from TLM. (N) 730
- ILEP Catalogue on Training, 1987. (N) 734
- Mr. Neil Winship new Director for LEPRO. (N) 735
- OXFAM-LEPRO: Packs of Teaching and Learning Materials for Leprosy; 1982-1986. (N) 367
- Robert Cochrane Fund for Leprosy. (N) 571
- XVI General Assembly of ILEP, Edinburgh, July 1986. (N) 168
- Teaching video on chemotherapy of leprosy available. (N) 736

- The Leprosy Mission International's (TLM) teaching and learning materials in leprosy.(N) 365
- Ulcer(s),**
- Metastasis of malignant plantar ulcer in lymph nodes in femoral triangle—a case report.
Bobhate, S. K., *et al.*(A) 590
- Microflora in the trophic ulcers of the foot in leprosy. Chatterjee, B. D., *et al.*(A) 375
- Plantar sensory threshold in the ulcerative foot. Birke, J. A. and Sims, D. S.(A) 184
- Reliability of the biothesiometer in measuring plantar vibratory thresholds. Theriot, S.,
et al.(A) 416
- Surgical treatment of plantar ulcers in leprosy. Rao, P. T. and Jena, S. K.(A) 395
- Ulcer border reshaping in the treatment of neuropathic plantar ulcers. Look, J. O.(A) 415
- Ultrastructure, (see also Electron microscopy),**
- An ultrastructural study of dermal nerves in early human leprosy. Chandi, S. M. and
Chacko, C. J. G.(O) 515
- Ultrastructural changes in the blood vessel in dermal lesions of leprosy. Mukherjee, A.,
et al.(A) 416
- [Ultrastructure of Langerhans' cell in the skin of borderline leprosy patients.] Liu,
J., *et al.*(A) 382
- Urine,**
- A Spot Test for Dapsone in Urine* by Han Huikeshoven. Hastings, R. C.(B) 574
- Antigens of *M. leprae* in urine during treatment of patients with lepromatous leprosy.
Olcén, P., *et al.*(A) 384
- Bedside urinalysis in untreated leprosy patients. Singh, R. G., *et al.*(A) 377
- Method for detecting sulfones in urine. Jaled, M. M., *et al.*(C) 560
- Methods for the detection of a specific *M. leprae* antigen in the urine of leprosy patients.
Kaldany, R.-R., *et al.*(A) 596
- U.S.A.,**
- Cultivable mycobacteria isolated from 32 newly captured armadillos (*Dasypus novem-*
cinctus) from Louisiana. Portaels, F., *et al.*(A) 788
- Dates for 1988 and 1989 seminars at Carville.(N) 571
- Dr. Paul Brand honored.(N) 368
- Dr. Richard A. Young 1987 Molecular Parasitology Award winner.(N) 736
- Leprosy cases for 1986.(N) 368
- The Heiser Program for Research in Leprosy 1988.(N) 572
- The nationalization of a disease: a paradigm? Soviero, D. J.(A) 370
- Treatment clinics for Hansen's disease.(N) 573
- Twenty-Second Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A., 20–
22 July 1987 (U.S.–Japan Cooperative Medical Science Program).(–) 767
- U.S.S.R.,**
- Academy of Medical Sciences. Juscenko, A. A.(N) 736
- Vaccination,**
- Attenuated *M. lepraemurium* vaccine nonprotective against *M. intracellulare* infection
in mice. Nakanishi, M.(A) 396
- Characteristics of human T-cell clones from BCG and killed *M. leprae* vaccinated sub-
jects and tuberculosis patients; recognition of recombinant mycobacterial antigens.
Mustafa, A. S., *et al.*(A) 750
- Delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy
vaccine.(A) 593
- Effects of ICRC antileprosy vaccine in healthy subjects. Chaturvedi, R. M., *et al.*(O) 657
- Humoral immune responses to *M. leprae* in human volunteers vaccinated with killed,
armadillo-derived *M. leprae*. Gill, H. K., *et al.*(A) 746
- In vitro* proliferation of lymphocytes from human volunteers vaccinated with armadillo-
derived, killed *M. leprae*. Gill, H. K., *et al.*(O) 30
- Limiting dilution analysis of the human T cell response to mycobacterial antigens from
BCG vaccinated individuals and leprosy patients. Brett, S. J., *et al.*(A) 743

Mass vaccination studies initiated. (India)	(N)	364
[Method of immunization with BCG-M vaccine with reduced antigenic content.]		
Yablokova, T. B., <i>et al.</i>	(A)	765
Preliminary study of a <i>M. leprae</i> bacterin vaccine in a human volunteer population in a nonendemic area. Millikan, L. E., <i>et al.</i>	(A)	383
The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man. Fine, P. E. M., <i>et al.</i>	(A)	745
World Health Organization (WHO),		
A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy—an <i>in vivo</i> and <i>in vitro</i> study. Revankar, C. R., <i>et al.</i>	(A)	587
Disability grading in leprosy; suggested modifications to the WHO disability grading form. Brandsma, J. W., <i>et al.</i>	(A)	394
Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malawi (Central Africa). Boerrigter, G. and Ponnighaus, J. M.	(A)	578
Results of a World Health Organization-sponsored workshop to characterize antigens recognized by mycobacterium-specific monoclonal antibodies. Engers, H. D., <i>et al.</i>	(A)	176
The First Joint THELEP-Sasakawa Memorial Health Foundation Workshop on Experimental Chemotherapy of Leprosy. Grosset, J., <i>et al.</i>	(S)	807
<i>Training in Leprosy</i> ; WHO publication.	(N)	168
WHO guidelines for skin smears.	(—)	421
<i>World Health Statistics Quarterly</i> . Maxwell, B. A.	(B)	170